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PEGylation of Niosomes
John A. Elliott
ABSTRACT
The research presented in this dissertation describes the creation and
characterization of a novel antibody-vesicle conjugate modified with polyethylene glycol
(PEG) that possesses enhanced binding to and uptake by inflammation-activated
endothelial cells with improved storage stability and longer shelf-life and potential
reduction in immunogenic potential compared to previous designs.
Targeted drug delivery provides an effective means of delivering therapeutic
concentrations of a drug to the site or organ of action. The drug is delivered using a
niosome, a vesicle with an aqueous core and a bilayer membrane composed of non-ionic
surfactants and cholesterol. Antibodies that recognize specific cell antigens are attached
to the niosome to complete the targeting molecule, an immuno-niosome (IN). When
functionalized PEG, a water soluble, biologically inert polymer, is attached to proteins, it
can protect the protein, increasing its half-life in vivo. The immuno-niosome synthesis
process is modified to include PEG incorporation into the niosome membrane, a process
known as PEGylation.
Since the vasculature connects the entire body, immuno-niosomes targeted to
endothelial cells were used. When endothelial cells are activated during disease, stress
and injury, certain receptors are expressed and upregulated. One such receptor, CD44, is
upregulated in response to vascular inflammation associated with atherosclerosis.
viii

The research hypothesis is that the addition of polyethylene glycol to the drug
delivery vesicle (immuno-niosome) using cyanuric chloride linking chemistry will
improve colloidal stability and binding performance of the PEGylated immuno-niosomes
to endothelial cell surface receptors expressed during an inflammatory response. The
research presented in this dissertation provides the following evidence to support this
hypothesis:
Construction and characterization of a modified drug delivery vesicle using
non-ionic surfactants conjugated with PEG and functionalized with antibodies
against endothelial cell surface receptors (PEGylated immuno-niosomes)
improves the colloidal stability over previously designed vesicles.
Binding of PEGylated CD44-IN to activated endothelial cells is improved
over previously designed vesicles.
Binding of PEGylated CD44-IN to activated endothelial cells under
physiological conditions (flow) is demonstrated.
Uptake of PEGylated immuno-niosomes by activated or injured endothelial
cells is demonstrated using confocal microscopy.

ix

1.

Project Background
Generally, the most effective and least toxic method of delivery of a therapeutic

agent is targeting directly to the site of action. Therefore, methods to enhance and
improve the design of targeted delivery vesicles are increasingly important to avoid the
deleterious health and drug dilution effects associated with systemic administration. In
1965 Bangham et al., described the liposome, a self-assembly bilayer phospholipid
vesicle composed of the cell membrane materials [1-3]. They determined that ions
encapsulated within the liposomes could diffuse out, similar to the process of particle
diffusion across a cell or biological membrane. Then, in the 1970's, Gregoriadis
determined that liposomes could be used to encapsulate proteins, chemotherapeutic drugs
and other therapeutic agents [4]. Also, in the 1970's, scientists in the cosmetics industry
developed niosomes, bilayer membrane vesicles composed of non-ionic surfactants [5,
6]. Since the phospholipids in liposomes are prone to oxidation, niosomes offer better
stability and shelf-life [7]. Next, with the advent of monoclonal antibody production in
1975 by Schwaber and Cohen [8], targeting specific sites located on cellular targets
became feasible. Additionally, the grafting of small molecular weight drug molecules to
polymer chains, e.g. polyethylene glycol (PEG), was reported to alter the immunological
properties of the molecule [9] and also reduce renal excretion of the molecule [10, 11].
Therefore, to improve the delivery vesicle (niosome) circulation time and provide
colloidal stability, a biodegradable polymer chain made from polyethylene glycol is
attached to the niosome surface, a process known as PEGylation. The hydrophilic PEG
1

chain attracts water molecules to the vesicle surface and this hydration inhibits plasma
protein attachment. Allen et al. and others have shown that PEGylation inhibits
reticuloendothelial system uptake and provides a site for antibody conjugation that is
extended away from the vesicle surface [12-15]. During the vesicle production process,
the functionalized surfactant, PEG, is incorporated into the membrane of the niosome.
Antibodies targeted to a specific cell surface receptor are conjugated to the terminal end
of the PEG chain, creating the immuno-niosome [16, 17]. In many disease states, e.g.
trauma, atherosclerosis, infection and inflammation, specific receptors are expressed on
the endothelial cell surface [18, 19]. For example, when exposed to cytokines and
abnormal shear stress, endothelial cells become activated, initiate an inflammatory
response and express cellular adhesion molecules [20]. Cellular adhesion molecules are
transmembrane glycoproteins involved in leukocyte recruitment, adhesion and
transmigration, thus making them potential targets for targeted delivery vesicles [20-23].
In particular, CD44, a smooth muscle and endothelial cell surface receptor, is involved in
inflammation-mediated processes, making it an attractive therapeutic target [24]. CD44
plays a critical role in inflammation associated with atherosclerosis, the buildup of plaque
causing hardening of the arteries and progression to heart disease. Blocking antigen
binding to the activated cell surface CD44 can reduce evidence of inflammation [18].
CD44 is also a potential target for solid tumor cells that express the cell surface receptor
and in some metastatic cancers where elevated levels of soluble CD44 can be found in
the circulation [25-28]. PEGylated immuno-niosomes are antibody-conjugated targeted
delivery vesicles made from PEGylated non-ionic surfactants, shown in figure 1.0.

2

Cholesterol
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Figure 1.0

PEGylated Immuno-niosome

The research hypothesis is that the addition of polyethylene glycol to the targeted
delivery vesicle (niosome) using cyanuric chloride linking chemistry will improve the
colloidal stability and binding performance of the PEGylated immuno-niosomes to
endothelial cell surface receptors expressed during an inflammatory response. Through
successful completion of the proposed aims in table 1.0, we provide a stable targeted
delivery vesicle, the PEGylated immuno-niosome, capable of delivering therapeutic
agents to specific cellular sites with high specificity.
Table 1.0
Aim 1

Project Aims

Construct and characterize a modified vesicle design using non-ionic
surfactants conjugated with PEG and functionalized with antibodies
against endothelial cell surface receptors (PEGylated immuno-niosomes).

Aim 2

Compare and observe binding of PEGylated immuno-niosomes to
endothelial cell surface inflammatory receptors.

Aim 3

Develop vesicle designs and techniques for in vivo delivery and imaging
of the PEGylated immuno-niosomes.
3

1.1.0

Drug Delivery Introduction
Design of a targeted drug delivery molecule requires knowledge of biology,

transport phenomena and pharmacokinetics. Integrating the knowledge derived from
these fields provides the foundation for modern research and development of most drug
delivery vesicles and conjugates. Therapeutic agents can be delivered by various routes,
e.g. oral, ocular, rectal, bronchial, transdermal and systemic. Most of the methods use the
cardiovascular system for distribution and removal of the agent once it has entered the
body. The cardiovascular system provides the driving force and infrastructure for the
distribution of the therapeutic agent throughout the body. Depending on the location of
the targeted site, distribution is carried out by diffusive and convective forces. When the
blood is used to transport material through the body, the point of first contact for the
targeting vesicle is the membrane of the endothelial cell surface.
1.1.1

Basics of Pharmacokinetics
Pharmacokinetics is the study of how the body distributes, absorbs, metabolizes,

and clears a drug after administration while pharmacodynamics describes the biochemical
and physiological effects of the drug on the body. The basic overview of the process of
pharmacokinetics is described by the acronym LADME which represents Liberation (L),
Absorption (A), Distribution (D), Metabolism (M) and Excretion (E). These processes are
not discreet as some can take place simultaneously. For example, simple compartment
models can be used to estimate serum levels in order to prevent the occurrence of
nephrotoxicity.
Inputs and outputs are the two types of operation described by LADME.
Liberation and absorption describe input processes where liberation is the release of the
4

drug from its original form and absorption is the movement of the drug from its original
site of administration into the blood stream. Distribution, metabolism and excretion are
output operations. Distribution is where the drug diffuses or travels from the intravascular
space into the tissue. Metabolism is where the drug is broken down or converted into
forms that are easy to eliminate. Excretion is the elimination of the original compound or
its metabolites from the body through renal, hepatic or pulmonary routes.
In the design of drug delivery molecules, the first thing to consider is how the
drug is to be administered or introduced into the body. Drugs can be delivered by site
specific methods such as ocular, dermal and bronchial or by broader distribution methods
of delivery such as oral and intravenous routes. The dermal methods are based on
adsorption through the skin by a patch that releases the drug over time. The drug is
absorbed into the blood and distributed, e.g. nicotine and nitroglycerine patches. Oral
methods of delivery use pills containing simple starch or gelatin binders to control release
rates in the gastrointestinal tract (GI), with the latter providing a slower release rate in the
stomach and intestine. A more sophisticated oral delivery method uses an osmotic pump
across a polymer shell so the drug can be delivered for a longer time. The drawback to
oral delivery methods is the harsh environment of the GI tract and the low absorption
rates of some drugs from the GI tract into the blood. The benefit is greater compliance
since typically the drugs can be taken by the patient without aid from a medical
professional and without the pain or complications that can be associated with
intravenous delivery methods. The route chosen for this study is the intravenous route
since the entire dosage of the administered drug reaches the circulatory system where it is

5

then distributed throughout the body prior to clearance by hepatic, renal and proteolytic
enzyme routes.
1.1.2

Compartment Models
When the drug enters the blood stream, the central volume (Vc) describes the

volume of blood in the vessels. This includes any tissues that are highly perfused with
blood and where the drug may distribute. The peripheral volume (Vp) describes blood in
the tissues outside of the central volume. Together Vc and Vp make up the volume of
distribution (Vd), which is the total fluid volume the drug is dissolved in [29]. Together,
the terms Vc, Vp and Vd are used to approximate the amount of drug in the body, peak
serum levels and the clearance of the drug from the body. The clearance (Cl) of the drug
from the blood is another important term that describes the behavior of the drug in vivo.
The rate of drug clearance is described by a constant called the elimination coefficient
(kel), which describes the fraction of drug eliminated per unit time. The constant is
patient-specific because it is based on the capacity and functionality of specific organs
that can be impacted by disease and the administered drug treatment. The clearance
calculation is shown in equation 1.0.
Cl = kel*Vd

Equation 1.0

The simplest way of characterizing a drug in the body is to use first order kinetics
and a single compartment model. In reality, first order kinetics holds up for most drugs
while the single compartment model works if serum samples are collected after the drug
moves into the tissues. The one compartment model is used for drugs that perfuse rapidly
while the two compartment model takes into account the distribution phase. When
graphing the two models, the one compartment model will yield a straight line on a
6

logarithmic y axis. The two compartment model yields a biphasic line on the same graph,
indicating the distribution phase. Some drugs, when administered by intravenous infusion
over a time course, will follow a three compartment model consisting of distribution,
elimination and tissue release. In encapsulated drug delivery design, the tissue release of
the drug can be coordinated with the time release from the vesicles. This is a beneficial
attribute of encapsulated delivery methods since drug plasma concentrations are
maintained for long time periods without the initial high drug plasma concentrations
associated with non-encapsulated delivery techniques.
The body can be modeled as a set of compartments connected in parallel and/or
series with the blood plasma as the conduit between the organs, as shown in figure 1.1.

Figure 1.1

Simple Compartmental Model

With rate constants representing the coefficients for drugs entering and leaving a
particular compartment (k12, k21), the liver and kidneys act as a sink (k20) where the
drug is metabolized and/or extracted from the plasma through hepatic and renal
clearance. This multiple compartment model is still incomplete because there are
intercellular and extracellular space interactions and intracellular compartment
interactions within each organ. More advanced modeling is being investigated in order to
7

incorporate physiological data from experiments [30]. Another method used to
characterize the drug in the body is to take into account the complex design of the
vascular bed and to implement fractal analysis [31, 32].
1.2.0

Introduction to the Cardiovascular System
The major components of the cardiovascular system are the heart, vessels and

blood circulated throughout the body. The entire vascular system is lined with endothelial
cells providing a blood contact surface. Therefore, the cells play an active role in the
cardiovascular system. The system is considered a closed loop because it is a sealed
system where all the fluid is maintained and circulated within an enclosed body. It should
be noted that a water cycle exists where fluids are absorbed through the GI tract,
replenishing the large water content that leaves the system through renal excretion, sweat
and respiratory function. The system provides transport of vital nutrients and fluids to all
the organs in the human body making it an attractive avenue for drug delivery schemes.
Because the operation of the cardiovascular system is essential for life, it is also a target
for therapeutic intervention and treatment.
1.2.1

Blood
The fundamental role of blood is maintenance and homeostasis. It is a fluid

composed of a multitude of components ranging from cells to proteins and trace minerals.
Blood density is very close to pure water as shown in table 1.1, 1050 kg/m3 compared to
1000 kg/m3.

8

Table 1.1

Physical Properties of Blood

Property

Values

Density

1050 ± 7 [kg/m3] @ 37°C

Viscosity at shear rate

3.26 ± 0.43 [mPa*s] at shear rate of 100 [1/s]
4.37 ± 0.60 [mPa*s] at shear rate of 50 [1/s]
5.46 ± 0.84 [mPa*s] at shear rate of 1 [1/s]

pH

7.4 ± 0.05 [H+]

Osmotic colloidal pressure

284 [mm H2O]

The cellular component of blood can be divided into three main groups with
subtypes as shown in table 1.2. The three main cell types are erythrocytes or red blood
cells (RBC), leukocytes or white blood cells (WBC) and thrombocytes or platelets.
Whole blood contains all the cellular and fluid components. Plasma contains the whole
blood soluble factors only, with the cells separated out by centrifugation. Once whole
blood has clotted, the remaining liquid component is serum. It is similar to plasma except
that it lacks the clotting factors. The plasma makes up approximately 55% of the blood by
volume and carries nutrients, proteins and trace minerals and acts as a pH buffer. The
plasma is composed primarily of water and contains numerous low molecular weight
organic and inorganic materials and about 7% protein, e.g. albumin, fibrinogen and four
major groups of globulins.

9

Table 1.2
Type

Blood Cell Types

Sub Type

Function

Erythrocytes

Red Blood Cells

Carry oxygen to tissues in the body.

Leukocytes

Neutrophil

Bacterial and fungal targeting.

Eosinophil

Parasite targeting and allergy mechanisms.

Basophil

Contains histamine and heparin, involved in
specific inflammatory and allergic processes.

Lymphocytes

NK cells remove tumors and viral-infected

(Natural Killer cell)

cells by cytokine induced apoptosis.

(B cell and T cell)

B and T cells are frontline agents in the
adaptive immune system.

Monocyte

Replenish macrophages and fight infection.

Thrombocytes Platelets

Regulation in blood clotting and inflammation.

A Newtonian fluid is described as a fluid that is non-compressible. The viscosity
is a function of temperature and pressure only and is described by Newton’s Law of
Viscosity where the shear stress
a constant of proportionality

is a function of the velocity profile

multiplied by

as shown in equation 1.1.
Equation 1.1

Blood can be approximated as a Newtonian fluid when circulating in large vessels.
However, when the vessel radius approaches that of capillaries, the red blood cells and
plasma separate into two phases and blood can no longer be considered a Newtonian
fluid. The blood flow is described as smooth (laminar) or turbulent depending on the
10

fluid path. In smooth flow, there are no disruptions in the axial direction and the cross
sectional velocity patterns are described as plug or parabolic. In plug flow the cross
sectional velocity is constant, creating high shear rates that act on the vessel wall. In plug
flow it is assumed there is no boundary layer at the wall surface. When the velocity
profile is parabolic, the fluid in the center of the vessel has the maximum velocity and the
fluid at the wall has the slowest velocity. The parabolic profile creates conditions that can
impede particles from reaching the vessel wall. This condition was first described by
Segre and Silberberg in 1962. The phenomenon causes particles that are near the wall to
migrate toward the axial position and particles that are in the axial position migrate
toward the wall. When blood is initially ejected from the heart, it travels through the large
arteries in a plug profile which becomes parabolic as the cycle continues. This effect is
less pronounced as the blood travels further away from the heart into smaller vessels (not
including the capillaries). Turbulent flow occurs at bifurcations and in pathological
conditions such as atherosclerosis where hardening of the arteries and plaque formation
disrupt the normal blood flow. Fluid flow can be described by the velocity profile,
pressure drop and the wall shear stress where the difference in pressure is the driving
force causing fluid flow. Blood is circulated based on the principle that a fluid flows from
an area of higher pressure to lower pressure, analogous to heat flow. The ventricles in the
heart contract and force the blood out, creating the driving force, so the blood will move
from an area of higher to lower pressure.
1.2.2

Heart
The human heart is a four chamber pump driven by and composed of myocardial

muscle tissue and it provides the driving force for blood circulation through the entire
11

system. The myocardial muscle tissue is surrounded by the pericardium, a tough inelastic
multilayered tissue. The inner walls of the myocardium are lined with endocardial tissue
composed of endothelial cells covering trabeculae. The left and right coronary arteries are
positioned on the outer surface of the muscle tissue and feed blood to the myocardial
muscle. To control the direction of blood flow, there are four valves, two valves that are
actuated by papillary muscles and two cuspid valves that are passive and are operated by
the pressure differential across the valve.
1.2.3

Circulation
The blood is returned from the body to the right atrium through two veins, the

superior and inferior vena cava. Blood flows from the right atrium through a tricuspid
valve into the right ventricle and is pumped through the right and left pulmonary arteries
to the lungs through a semilunar valve. In the lungs, a gas exchange occurs between the
air in the alveolar sacs and the lung capillaries. After this exchange process, the blood is
now ready to deliver oxygen to the various tissues in the body. The oxygenated blood is
returned to the heart through the right and left pulmonary veins to the left atrium. The
blood traverses across the mitral valve into the left ventricle where it is ejected across the
aortic valve into the aortic arch and the descending aorta. From the major arteries, the
vessels continue to branch out into smaller arteries, transitioning from the arterioles to the
smallest group of vessels called capillaries. The arterioles are responsible for the
peripheral resistance in the cardiovascular system; this resistance is directly related to
arterial pressure from the restriction of blood flowing from the arteries through the
arterioles. The capillaries contain the largest total cross-sectional surface area in the body
and are present in every tissue. They contain a single layer of endothelial cells
12

surrounded by basal lamina. Capillaries are the pathway for the delivery and exchange of
oxygen, carbon dioxide and critical nutrients to the surrounding tissues in the body,
making them a focus for targeted drug delivery techniques. The fluid that carries nutrients
from the capillaries is collected in the lymphatic ducts. The lymphatic system is
responsible for removing fluids from the tissue interstitial spaces around the body and
returning those fluids to the blood stream. The blood is returned to the heart by a
complementary set of vessels called veins which completes the closed loop of the
cardiovascular system.
1.3.0

Cell Introduction
Cells are contained within the tissues of all living creatures. Cells can be divided

into two distinct types, eukaryotes, cells with a nucleus and well-developed intracellular
organelles and prokaryotes, cells without a discrete nuclear membrane. The basic
structure of a cell consists of a fluid core surrounded by a bilayer lipid membrane. The
internal space of eukaryotic cells, the cytoplasm, is a fluid core with membrane-bound
organelles and a nucleus. The cytoplasm contains many small and large molecules and
the cell transports material into the cytoplasm and between organelles using small
membrane-bound vesicles. The nucleus contains the information the cell needs to
function and replicate. Energy for cellular processes is generated in the mitochondrion.
Mitochondria produce adenosine triphosphate (ATP) that is used as an activated energy
carrier in biosynthesis reactions and is also responsible for cellular functions such as the
cell cycle and growth. The nucleus is surrounded by a double layer membrane with pores
that allow the transfer of material. Ribosomes within the cytosol are sites of protein
synthesis where messenger RNA transcribed in the nucleus is translated into protein on
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the ribosomes. An additional multifunctional cytoplasmic organelle is the endoplasmic
reticulum (ER). The rough endoplasmic reticulum (RER) is coated with ribosomes. The
formed proteins can be further modified on the surface of the RER. There is another part
of the ER called the smooth endoplasmic reticulum (SER) that is responsible for
specialized functions like lipid and steroid production. The proteins formed at the free
ribosomes, RER and SER are transported to an organelle called the golgi apparatus. The
golgi apparatus functions primarily as a cellular post office where the material is sorted,
packaged and sent to the proper destination within the cell. Lysosomes import and
recycle materials using digestive enzymes. Lysosomes have an internal pH of 4.8.
Materials transported into the cell by endocytotic vacuoles are typically shuttled to an
acidic vacuole called an endosome. The endosome sorts recyclable materials to the
plasma membrane or delivers them to the lysosome. This transport and recycling feature
is important in developing drug delivery strategies because therapeutic agents can be
degraded by the acidic conditions.
1.3.1

Endothelial Cells
The vasculature is lined with a single layer of endothelial cells providing the

blood contact surface in the heart, arteries, veins and lymphatic system. The endothelial
cell is a subtype of the epithelium which lines human body cavities and tissue structures.
One feature of the endothelial cell type is that it expresses the E-cadherin adhesion
molecule on its surface. There are differences between arterial and venous endothelial
cells and it has been shown that the genetic coding determines the cell phenotype [33]. In
fact, different phenotypes are seen in the five different types of endothelial cells found in
the heart (endocardial, coronary, arterial, capillary and lymphatic) [34]. There are
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organizational/orientation differences between the endothelial cells (arterial versus
ventricular) covering the aortic valve. The cells are aligned in different patterns to
compensate for the physiological stresses they encounter. A transmission electron
microscope image of an endothelial cell on an aortic valve is shown in figure 1.2

Figure 1.2

Endothelial Cell on Aortic Valve (arterial)

Variations in permeability of the endothelial cell layer in large arteries and
capillaries are caused by the underlying structural components of the different vessels.
The large arteries transport blood and the capillaries function to deliver vital molecules
and fluids to the tissue intracellular spaces. The main arteries allow passage of oxygen
and small molecules from the blood through the endothelial cells into the arterial
substructure to maintain the smooth muscle cells. The lymphatic system is a low flow
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system that maintains intracellular fluids and has the potential to become a target for
developing anti-inflammatory treatments [35]. There are also interactions between tumor
cells and the lymphatic system making it a focus for anti-cancer treatment strategies.
1.3.2

Endothelial Cell Mass Transport
For intravenous targeted drug delivery, the endothelial cell surface is the first

point of contact, whether the surface of the cell is the intended site of therapy, the drug is
to be transported into the cell, or the drug needs to cross the endothelial cell barrier to
reach the underlying tissues. The selection of the cell surface receptor is matched to the
delivery vesicle using knowledge of the receptor’s temporal expression and binding
affinity. The targeting strategy dictates the size and composition of the delivery vesicle to
provide the behavior required in the area of interest since it may need to overcome
convective forces due to blood flow momentum in great vessels or shear forces in smaller
vessels. Depending on the application of the therapeutic agent, the mass transport
interactions with the endothelium can be characterized as: a reactive surface, a reactive
wall or a semi-permeable membrane shown in table 1.3 [36].
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Table 1.3
Process
Reactive Surface

Endothelial Transport Equations [36]
Equation

Cs/Cb =1/(1+ Dar /Sh), Equation 1.2

Important Conditions
Dar << Sh
Dar >> Sh

Semi-Permeable

Cs/Cb =1/(1+ Dac /Sh), Equation 1.3

Dac >> Sh

Ps,A/Pb,A=1-Daw/Sh, Equation 1.4

Dar << Sh

Membrane
Reactive Wall

Dar ≈ Sh

As a reactive surface, Michaelis-Menten kinetics (MMK) are used to model the
interactions at the surface. MMK describe biological reactions involving enzymes and
assume the reaction is irreversible and that the product does not bind or occupy the
enzyme. The Damkohler number (Da) is a ratio relating the reaction rate to the mass
transport rate and the Sherwood number (Sh) is used to relate the convective and
diffusive forces. When the surface concentration is equal to the concentration found in
the blood stream, reactive surface equation 1.2 is reaction limited. When the Damkohler
number is much greater than the Sherwood number (Dar >> Sh), the reactants are present
at the wall in concentrations high enough or in excess for the reaction. The diffusive and
convective forces that bring the reactants from the blood stream to the cell wall do not
influence the reaction.
When the endothelium is described as a semi-permeable membrane for small
molecules, equation 1.3 shows that when the Damkohler number is much larger than the
Sherwood number, the system is transport limited or fluid-phase limited. In larger vessels
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this means it will be more difficult for large molecules and particles to move to the
endothelial surface. In contrast, smooth flow patterns will allow smaller particles to
diffuse to the endothelial surface more quickly. This illustrates how a vesicle that is
attached to the endothelial surface at a site of therapeutic interest can take advantage of
this process. In the capillary vessels, there is a phenomenon called shear thinning that
takes place. This occurs because the diameter of the red blood cell is similar to that of the
vessel. The red blood cells separate from the plasma and travel down the center of the
vessel and the plasma is pushed toward the wall surface creating a non-Newtonian liquid
with two distinct phases. The effect of the plasma being located near the wall creates a
fluid phase that the delivery vesicle will occupy when in close proximity to the binding
site on the vessel wall.
At the reactive wall, there is consumption or a sink on the mass balance. The act
of oxygen transport from the blood stream to the vessel wall is an important process that
is required to maintain homeostasis of the vessel. Equation 1.4 shows that when the
Damkohler number is much smaller than the Sherwood number, the reaction is limited by
the reaction rates associated with the wall, and transport phenomena does not play an
important role. As the Damkohler and Sherwood numbers approach one another, the
reaction is limited by transport of the reactant to the wall, and convective and diffusive
forces become important. This has been used to explain endothelial dysfunction in
coronary arteries leading to a leaky vascular wall and allowing the influx of low density
lipoproteins, a primary step in atherosclerotic plaque formation.
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1.3.3

Endocytosis
Endocytosis is the uptake of nutrients, fluids, large and small molecules and

particles in cells. There are two main pathways for endocytosis, phagocytosis and
pinocytosis. Phagocytosis is described as a process where the cell engulfs large particles
(>250nm) by folding its membrane around the particle. Pinocytosis is a process where a
cell uptakes liquids and small molecules (<150nm) inside pits that are formed in the cell
membrane and that pinch off forming vacuoles that carry the contents to various
intracellular locations [37]. Phagocytosis is a process that specialized cells in the immune
system use to remove pathogens and debris and is the process that macrophages use to
complete housekeeping duties throughout the body. Phagocytosis is a major pathway for
specialized cells like macrophages, but is rare in endothelial cells in situ. However, Muro
et al. reported that endothelial cells can internalize large particles up to 5 um in size [22].
Considering the rarity of phagocytosis in endothelial cells in vivo, it has not been a focus
of most targeted delivery schemes. However, since macrophage activity is a process
associated with tissue injury and inflammation, the macrophage is an attractive target for
therapeutic treatment [38]. Pinocytosis and receptor-mediated pathways are also used to
deliver a payload to the site of interest. Pinocytosis is a non-specific uptake of
extracellular fluids and small molecules and can be used to deliver a reservoir to the cell
surface. The reservoir contents are eluted into the extracellular fluid and diffusion
becomes the driving force for delivery. Uptake pathways are described by four main
groups: macropinocytosis, clathrin-mediated endocytosis (CME), caveolae-mediated
endocytosis (CavME), and clathrin-caveolae-independent-internalization [39, 40]. CME
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and CavME both provide non-specific pathways for the uptake of adsorbed molecules
through invaginations found on the cell membrane.
The caveolae are small 60-80 nm plasma membrane invaginations used for
endocytosis, exocytosis, transcytosis and the internal transport of macromolecules [41].
They do not have a large volume and are typically lined with receptors such as gp60, an
albumin specific receptor. The CavME pathway has been well studied and provides a
promising route for delivery to the endosome, caveosome and the cell nucleus [42]. The
selection of these different delivery routes is based on interactions of the surface lipid
rafts, integrins and proteins. Caveolae are involved in the transcytotic and exocytotic
processes which are directed by secondary protein interactions.
1.4.0

Cell Surface Receptors
Targeted drug delivery can be used to target cell types based on size, charge and

binding schemes using cell surface receptors and receptors found within the pits formed
during pinocytosis. Cells continually express protein and carbohydrate receptors for
ligands both externally on their membrane surface and internally for a variety of
functions. The receptors that are expressed vary between cell types and some of them
may only be up-regulated during certain stages of disease or injury, such as receptors for
inflammation. Cell surface receptors may be either integral or peripherally attached to the
membrane. Peripheral receptors are composed of proteins that are temporarily attached to
the cell membrane and function in a regulatory manner. They are not as common as the
integral types. Peripheral and integral membrane receptors are required cellular
homeostasis. The functions of the receptors vary from adhesion, signaling and
communication to the extracellular matrix and other cells, as well as triggering cellular
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processes such as apoptosis, endocytosis and mitosis. Transmembrane receptors are
integral in nature and their protein structures penetrate through the membrane into the
cytoplasm for intracellular signaling. The integral membrane proteins are typically made
from alpha helices and beta sheets. Integral proteins can be grouped into six categories
based on how the structure interacts with the lipid membrane of the cell (table 1.4, [14]).
Table 1.4
Type
I

Integral Membrane Protein Types

Description
One helix structure with terminal amino group on the outside and carboxyl
group on the inside of the cell membrane.

II

One helix structure with terminal carboxyl group on the outside and amino
group on the inside of the cell membrane.

III

Multiple helix structure penetrating the cell membrane using a single
polypeptide.

IV

Multiple helix structure formed by different polypeptides creating a channel
through the membrane.

V

Proteins that are attached to the lipid membrane by covalently linking to
lipid molecules without passing through the membrane.

VI

Single polypeptide structure that passes through the cell membrane and has
a type V lipid anchor.

The delivery vesicle encounters the cell membrane surface receptor and this is the
first target for most delivery schemes. A secondary interaction with peripheral receptors
could provide additional targeting benefits. Inflammatory receptors are cell surface
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receptors that are up-regulated by the cell during conditions of disease, injury and
infection. Inflammatory receptors include the cellular adhesion molecules (CAMs) which
can be expressed on the cell surface, intracellularly or within the extracellular matrices of
tissues. The CAM family can be grouped into five groups based on protein type. These
are: immunoglobulins, selectins, addressins, integrins and cadherins. Of these five, three
have been used for targeting the arterial endothelium. The CAM groups, the
immunoglobulins, selectins and cadherins, provide potential binding sites for therapeutic
particle delivery (table 1.5).
Table 1.5
Type
IgG

Common Cell Adhesion Molecules (CAMs)

Name
ICAM-1

Function
InterCellular Adhesion Molecule 1 is expressed by leukocytes
and endothelial cells and is responsible for leukocyte
extravasation into tissues from the blood stream during an
inflammatory response [43].

IgG

CD44

Is involved in cell to cell interactions and is expressed by
endothelial cells during inflammation, atherosclerosis,
rheumatoid arthritis and cancer [44-46].

IgG

VCAM-1

Vascular Cell Adhesion Molecule-1 is expressed by activated
endothelium during inflammation. It is expressed by large and
small vessels and is associated with atherosclerosis. Some
melanomas use it to attach to the endothelial cell surface [4749].
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Table 1.5 (Continued)
IgG

PECAM

Platelet Endothelial Cell Adhesion Molecule is found on
endothelial cells, platelets, macrophages, neutrophils and
Kupffer cells. It plays an important signaling role in
thrombosis and between macrophage cells and dying
neutrophils [50, 51].

Selectin

E-selectin

A low affinity cell adhesion molecule expressed only by
endothelial cells during inflammation. It allows leukocytes
to bind in a reversible manner known as leukocyte rolling
[52, 53].

Selectin

P-selectin

A cell adhesion molecule similar to E-selectin but
expressed very quickly as it is stored in endothelial cells
preformed and does not need to be synthesized [54, 55].

Selectin

L-selectin

A cell adhesion molecule that is associated with lymphatic
endothelial cells. It functions like E-selectin and P-selectin
and is used for leukocyte recruitment [56-58].

Cadherin VE-cadherin

VE-cadherin is an intracellular adhesion molecule that is
responsible for the integrity of the junctions between
endothelial cells [59, 60].

Cadherin T-cadherin
H-cadherin

T-cadherin is highly expressed in the heart and aorta and is
upregulated in atherosclerotic lesions and tumor
penetrating blood vessels [61-63]. H-cadherin is associated
with cancer and tumor development [64-67].
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1.4.1

Proteins
Proteins are responsible for most of the functions that take place in a cell. They

are the most complex molecules found with regard to their structure and function. They
are comprised of a combination of amino acids that have side chains that give them
distinct chemical functions. Polypeptides are formed when the amino acid molecules are
linked together by a covalent peptide bond forming linear polymers with functional side
chains. Some proteins have a negative or positive charge, some are uncharged or polar,
and some are hydrophilic. The noncovalent interactions between the side chains cause the
linear polypeptide sequence to take shape. Hydrogen bonds, ionic bonds and van der
Waals attractions are responsible for secondary structure of the molecule. The peptides
will shift to a conformation with the lowest energy level. This is determined by
temperature, pH and the solvent. The two major structures that are commonly formed are
the alpha helix and beta pleated sheet. Βeta pleated sheet structures resemble ribbons with
polypeptide chains running in the same direction in a parallel structure or an alternating
direction forming an anti-parallel sheet structure. Proteins form alpha helix structures to
cross the cell membrane.
1.4.2

Antibodies
The immunoglobulin superfamily (IgSF) is a large group of cell surface and

soluble proteins made from amino acids that contain an immunoglobulin (Ig) domain.
The Ig domains contain two layers of β pleated sheets and three to four anti-parallel
polypeptide chains. The Ig structure anti-parallel beta sheets are characterized by the
conserved disulfide bond that links the two sheets together. All the proteins with these
immunoglobulin domains belong to the IgSF (the structures are involved with cell
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recognition, binding, adhesion and receptors for antigens and cytokines). Antibodies
belong to this superfamily and bind to their specific antigens with high affinity and
selectivity [68]. These antibodies are used to target inflammatory receptors in the
described studies. There are five different classes or isotypes of human antibodies shown
in table 1.6. They contain polypeptide structures grouped into regions called chains with
constant regions that are conserved and variable regions that form the binding sites for
specific antigens. All five classes have the same fundamental four chain structure made
from a pair of identical heavy chains and a pair of identical light chains held together as a
tetramer with disulfide bonds. In 1959 Porter, showed that the antibody could be cleaved
using the proteolytic enzyme papain, into three major structures that compose 90% of the
original molecule (figure 1.3). He noted that two of the structures retained the ability to
bind with antigen and had nearly identical chemical properties. He also noted the third
fragment had very different chemical properties and did not bind with antigen. This was
the first clue that immunoglobulins had a “Y” structure composed of the three groups he
found after the papain digest. The two identical structures are called fragment antigen
binding arms (Fab) and the third region is called fragment crystalline (Fc) [69] (figure
1.3). The five classes of antibodies each have distinct heavy chains which are used for
classification, as listed in table 1.6.
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Table 1.6
Type

Heavy Chain

IgA

α

Human Immunoglobulin Types
Description

Dimer that is found in mucous and breast milk provides
protection from pathogen colonization [70]. Can survive
conditions in the gastrointestinal tract [71].

IgD

δ

Monomer that is located on the surface of B cells and
acts as an antigen receptor [72].

IgE

ε

Monomer that binds its Fc region to leukocytes and binds
to allergens to trigger the release of histamine. [73] It
also initiates an immune response to parasitic worms
[74], [75].

IgG

γ

Monomer and the immunoglobulin that is responsible for
the secondary immune response. Comprises 75% of the
immunoglobulin found in serum[76].

IgM

μ

Pentamer immunoglobulin that is the largest and first
found in the blood or in monomer form on the cell
membrane [77].

1.4.2.1

Immunoglobulin G
The IgG family of antibodies comprises 75% of the antibodies found in human

plasma. The four major classes of human IgG are IgG(1), IgG(2), IgG(3) and IgG(4) with
IgG(1) being the most abundant of the four classes [78]. Immunoglobulin contains
glycoproteins produced by specialized lymphocyte cells. These specialized lymphocytes
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originate from hematopoietic stem cells and terminally differentiate into plasma cells and
memory B cells. The genetic code that is developed during this maturation process is
based on four genes, the variable (V), diversity (D), joining (J) and constant (C) gene.
The cell line that produces IgG has the following lineage. The stem cells differentiate into
pro-B cells pre-B cells, and then immature B cells. At this stage, the cells are located in
the bone marrow and they are antigen independent. The cells then migrate into the spleen,
tonsils and other peripheral lymphoid tissues and some become mature B cells, and
collect in areas that are rich in helper T cells. These specialized areas in the tissues are
known as germinal centers. When the mature B cell is activated by a helper T cell, it
divides and differentiates into a centeroblast by a process called somatic hypermutation.
After somatic hypermutation, the precursor cell is called a centrocyte prior to becoming a
plasma cell or a memory B cell. During B cell maturation, the genetic code that is
responsible for the makeup of the variable binding region is determined through a process
called VDJ recombination. The variable chain has three domains that are encoded by the
V, D and J genes. During the VDJ recombination process, base pair changes are
introduced for both heavy and light chain variable regions. In this way, the immune
system is able to make a diverse group of antibodies that are able to recognize multiple
antigen types.
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Figure 1.3
1.4.2.2

Immunoglobulin G (IgG)

Monoclonal Antibodies
The advent of methods of monoclonal antibody production in the mid 1970’s was

made possible by Paul Erlich’s “magic bullet” concept. The technique was first
described in 1973 by Schwaber and Cohen and they reported being able to produce
human-mouse antibodies by fusing mouse myeloma and human peripheral lymphocytes,
creating hybridomas [8, 79]. There has been controversy over this paper and Kohler and
Milstein in 1975 reported production of monoclonal antibodies by fusing mouse
melanoma cells with spleen cells from an immunized mouse [80]. They were recognized
as the first group to produce antibodies using the hybridoma technique.
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1.4.3

CD44 Receptor
CD44, shown in figure 1.4, is a cell surface receptor that remains expressed on the

cell surface or that can be shed or released into circulation by enzymatic cleavage,
becoming soluble CD44 [27]. CD44 is involved in many functions including cell to cell
interactions with leukocytes and endothelial cells and remodeling of the extracellular
matrix during cell to substrate interactions in embryonic development [81]. There are
typically two forms of CD44, the standard and the variant form. A single gene with 20
exons encodes CD44, and the standard form is the most prevalent, consisting of exons 15, 16-18 and 20. Exons 6-15 are called variant exons v1-v10. The variant exons are
spliced in different combinations in the stem portion of the receptor [82].

Figure 1.4

CD44 Genomic Sequence and Receptor Structure [82, 83]
29

CD44 is a transmembrane glycoprotein in the cellular adhesion molecule family
and is the major receptor for hyaluronan [84]. CD44 is expressed by many cell types
throughout the body including the keratinocytes [85] and red blood cells [86]. The CD44
receptor, expressed by both endothelial and smooth muscle cells is involved in
inflammation-mediated processes, making it an attractive therapeutic target [24]. It has
been shown to play a critical role in inflammation associated with atherosclerosis, and
blocking binding to the CD44 receptor can reduce evidence of inflammation [18]. CD44
is also expressed on various cancer cell surfaces and has been implicated as a marker for
cancer when found in high levels in its soluble form in the circulation [25, 28, 44].
1.4.4

Intercellular Adhesion Molecule (ICAM)
Intercellular adhesion molecule (ICAM) is found in three forms (ICAM-1, ICAM-

2 and ICAM-3) and is part of the immunoglobulin superfamily. It is expressed by
cytokine-activated vascular endothelial cells, macrophages, fibroblasts, smooth muscle
cells, keratinocytes and leukocytes. The normal function of ICAM is to provide binding
between endothelial cells and leukocytes during injury and infection by binding to
leukocyte function association antigen (LFA) or macrophage-1 antigen (Mac-1). ICAM is
also a receptor for human rhinoviruses and malaria-infected erythrocytes [87]. ICAM-1, 2 and -3 are type I transmembrane glycoproteins that are all involved in the LFA immune
response [88].
ICAM-1 was first discovered in 1986 [89] followed by the discovery of ICAM-2
in 1989 [90] and finally ICAM-3 in 1992. ICAM-3 is expressed by lymphoid but not
endothelial cells [91]. The ICAM-1 and ICAM-2 receptors are normally expressed in low
concentrations on endothelial cells but are highly upregulated after exposure to the pro30

inflammatory cytokines, tumor necrosis factor alpha (TNF-α) and interleukin-1 (IL-1),
making them an attractive binding target for drug therapy. ICAM-1 is encoded by human
chromosome 19. It has a total of seven domains. Five are in the extracellular space with
D1 and D3 as active binding sites [92] as shown in figure 1.5.

Figure 1.5
1.4.5

ICAM-1

Vascular Cellular Adhesion Molecule (VCAM)
Vascular cellular adhesion molecule (VCAM-1) is a member of the

immunoglobulin superfamily and is encoded by human chromosome 1. It is expressed
only by cytokine-activated endothelial cells in large and small vessels, and like ICAM-1
it binds leukocytes via the leukocyte function association antigen (LFA) [93]. It differs
from CD44 and ICAM since it has two binding sites in domains 1 and 4 for very late
antigen (VLA-4) expressed by T and B lymphocytes, monocytes, basophils and
eosinophils [94] (figure 1.6). Metastatic melanoma cells bind to VCAM expressed on
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endothelial cells [95]. It has also been shown that the adhesion molecule facilitates
migration of leukocytes into the lymph nodes [96]. VCAM is upregulated at sites where
arterial atherosclerotic plaques develop during the progression of this chronic disease.
VCAM expression is associated with the recruitment of monocytes and macrophages that
infiltrate arterial tissue and venous grafts, making it an attractive drug delivery target [97,
98].

Figure 1.6
1.5.0

VCAM-1

Cytokines and Inflammation
Cytokines are extracellular signaling molecules that are required for cell-cell

communication. They share several properties, which include: secreted briefly and are
self limited, can be produced by multiple cell types, act on different cells types, action
can be redundant and can influence the production and action of other cytokines.
Cytokine chemical signaling can be grouped into autocrine, paracrine and endocrine
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action. Autocrines are chemical agents that influence or act on the cell from which it was
secreted. Paracrine action is where a cytokine acts on a different type of cell than the one
that secreted it in the same area of a tissue. Endocrine action is where a cytokine secreted
in the blood stream is distributed into tissues by blood and extracellular fluids. Cytokines
are classified into three major groups that describe their function: interleukins,
lymphokines and chemokines. Interleukins were first classified as molecules that were
produced by a population of blood leukocytes and that interacted with other leukocyte
populations [99]. However they are produced by other cell types and many newly
discovered cytokines are designated with the interleukin nomenclature to prevent naming
ambiguity [100]. Lymphokines are a class of cytokines that are produced by activated Tlymphocytes in response to specific immunity [101]. Chemokines are pro-inflammatory
cytokines released by cells and are used to signal or attract other cells to a site of injury or
infection. The name is derived from chemotactic cytokines. Two specific cytokines,
tumor necrosis factor alpha and interleukin-1, are further described in sections 1.5.1 and
1.5.2, because of their interactions in vascular tissues and one is used later in experiments
to invoke a desired reaction from cultured endothelial cells.
1.5.1

Tumor Necrosis Factor Alpha
Since inflammation is a cellular response to injury, stress or infection, cells will

upregulate specific receptors in response to those stresses. The inflammatory response is
defined by the recruitment of leukocytes to the affected tissue and a shift in the fluid
exchange balance through the arterial wall [102, 103].
Tumor necrosis factor alpha (TNF-α) and interleukin-1 (IL-1) are both mediators
of inflammation. The process of inflammation was elucidated by Menkin in 1959 when
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he described a mediator he called necrosin as being endogenous in nature. In 1975, the
mediator TNF-α was defined by Carswell and Old. It behaved like necrosin, previously
described by Menkin [104]. TNF-α is highly conserved among species [105] and its
function is concentration dependent. At low concentrations it is a pro-inflammatory
cytokine and causes the upregulation of endothelial cell receptors and activation and
upregulation of macrophages and leukocytes. At higher concentrations it causes cell
apoptosis and has anti-tumorogenic properties. [106]
1.5.2

Interleukin 1
Interleukin 1 (IL-1) was one of the first cytokines described by scientists, like

Menkin and Beeson in the 1940s as an endogenous pyrogen because of its ability to
induce fever when purified samples were administered to normal animals [107]. The
entire interleukin group contains over 30 members and IL-1 is a family of proinflammatory molecules containing 11 members, all encoded by separate genes [100].
Both IL-1 alpha (IL-1α) and beta (IL-1β), are pro-inflammatory molecules in their mature
or active forms. The molecules are encoded by a 7 exon gene on chromosome 2 of the
human genome and are produced as precursor peptides. The precursors are proteolytically
cleaved to become the mature or active forms.
1.6.0

Cardiovascular Disease
Cardiovascular disease is the number one killer of adults in the United States and

according to the American Heart Association, 864,480 Americans died in 2005 from
some form of cardiovascular disease. Cancer was responsible for 559,312 deaths and
accidents for 117,809 deaths. Coronary heart disease caused one in five deaths in the
United States in 2004 [108]. Coronary heart disease is caused by atherosclerosis, a
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pathological disease causing narrowing of the coronary arteries due to the buildup of
oxidized lipids, macrophages and smooth muscle cells in the vessel wall. This process is
characterized by an inflammatory response perpetuated by endothelial dysfunction [109]
followed by the accumulation of lipids [110], recruitment of leukocytes [111], and
activation of smooth muscle cells [112] which eventually form mature plaques. This
pathological process occurs over the course of several decades and can be described in
six stages. The first stage has been shown to start in as early as the first decade of human
life [113-115]. The start of lesion development occurs in areas of endothelial dysfunction.
The endothelial cells become permeable and express adhesion molecules on their surface.
In stage I lesions, some of the macrophages develop into isolated foam cells after
ingesting oxidized low density lipoproteins. In stage II lesions, the lipids accumulate
within the smooth muscle cells, the macrophage foam cells accumulate and both cell
types form distinct layers that are seen grossly as fatty streaks. The accumulation of
macrophages stimulates an inflammatory response in the tissue causing increased
production of cytokines. Stage III lesions contain the same cells and cholesterol esters as
seen in stage I and II lesions with the addition of extracellular lipid droplets. This
accumulation of extracellular material is the link between early and advanced stages of
atherosclerosis. Stages I, II and III can occur during the first three decades of life
respectively [116]. Advanced stages of atherosclerosis are described by atheromas,
lesions that disrupt the intimal structure. Stage IV lesions contain a lipid core caused by
the accumulation of extracellular lipids in a distinct region.
This core disrupts the normal intima, and tissue remodeling is initiated by
invasive macrophages and migrating smooth muscle cells. Stage V lesions can develop
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into three different forms. Type V(a) have multiple layers or cores separated by thick
fibrous tissue. Type V(b) lesions have a calcified lipid core, causing severe changes in the
elastic properties of the intima. Type V(c) is used to describe lesions with small or absent
lipid cores, but with extensive fibrous tissue. Stage VI lesions are stage V and IV lesions
that have further modifications. Type VI(a) lesions have surface disruptions, type VI(b)
lesions have either hematoma or hemorrhage associated with the lesion and type VI(c)
lesions have thrombotic deposits. These different types of surface modification are
sometimes called complicated lesions [117].
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2.

Construction and Characterization of Modified Vesicle Design
Vesicles for targeted drug delivery can be made from several different types of

materials such as natural or synthetic surfactants, polymers, peptides, minerals and
metals. Vesicles fabricated from semiconductors and single wall nanotubes have also
been used as drug carriers [118]. They are very stable and have long circulation times but
are not biodegradable and present possible long-term health risks. Membrane vesicle
designs using molecules that self-organize when placed into aqueous solutions and form
non-covalent structures provide a design that has been used in nature. This is the design
chosen for this study and the construction is described in the following sections.
2.1.0

Amphiphiles
Auto-assembly vesicles and cell membranes are formed from molecules called

amphiphiles. These are molecules that have two different domains with opposite
behaviors towards aqueous environments. Amphiphiles have one distinct region that
attracts water molecules (hydrophilic) while the other region repels water molecules
(hydrophobic). This property makes them a surface active agent also known as a
surfactant. Amphiphiles can be made from natural and synthetic surfactants as well as
peptides and co-block polymers. The molecule properties can be further described by
their tendency to dissolve in an aqueous liquid (hydrophilicity) or a fatty liquid
(lipophilicity), known as the hydrophilic-lipophilic balance (HLB). The HLB is
commonly described on a dimensionless scale where 0 is very lipophilic and 20 is very
hydrophilic.
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There are two major classes of surfactants, non-ionic and ionic. The ionic
surfactants can be cationic (positively charged), anionic (negatively charged) or
zwitterionic (both positive and negative domains in the head group) that can be positive
or negative depending on the pH of the solvent. The ionic and non-ionic surfactants have
hydrophobic tail sections composed of long hydrocarbon chains that are attached to
hydrophilic head sections with a large hydrodynamic radius compared to the tail section
as shown in figure 2.0. The difference in the hydrodynamic radius of the head and tail
section is responsible for the formation of the non-covalent structures made from the
aggregating surfactant molecules.

V = Volume
a = Area of hydrophilic
head group

L = length
Figure 2.0

Hydrodynamic Shell of a Surfactant Molecule

One equation describing this basic behavior of the molecule is the non-dimensional
critical packing parameter (CPP).
Equation 2.0
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In equation 2.0, “V” is the volume of the molecule, “a” is the effective head group area
and l is the hydrophobic tail chain length. Amphiphiles that have a CPP value below 0.5
will form micelle structures. Cylindrical micelles will form when the CPP is in the range
of 0.3 to 0.5. When the CPP range is between 0.5 and 1, amphiphiles will form both
vesicles and flexible bilayers. Therefore, this is the target range for the surfactants used in
this study. When the CPP range is equal to 1, then lamella and planar structures are
formed. Inverse micelles are formed when value of the calculated CPP is greater than 1.
2.1.1

Non-Ionic Surfactants
Non-ionic surfactants are synthetic amphiphiles that are commonly used as

detergent emulsifiers. The two surfactants used in this study are sorbitan monostearate
(Span 60) and polyethylene sorbitan monostearate (Tween 61). Both contain fatty acid
tails composed of approximately equal amounts of stearic acid (CH3(CH2)16COOH) and
palmitic acid (CH3(CH2)14COOH). Three hydroxyl groups attached to the head groups
makes the molecules hydrophilic. The Tween 61 molecule has three oligomeric chains of
polyoxyethylene used to tether the hydroxyl groups to the head of the molecule as shown
in figure 2.1.
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Figure 2.1
2.1.2

Molecules: Span 60 and Tween 61

Cholesterol
Cholesterol is a steroid which exhibits a slight amphiphilic tendency due to the

hydroxyl group at the head of the ring structure as shown in figure 2.2. Cholesterol, with
an HLB factor of 2.96 is used to stabilize the bilayer membrane by adding rigidity due to
the planar configuration of the molecule. Steroid molecules that are closely related to
cholesterol, such as β-cholestanol, β-sitosterol and stigmasterol can be used to tailor the
leakage and stability of the membrane [119].
HO

CH3

H3C
CH3

H3C
CH3

Figure 2.2

Cholesterol
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2.2.0

Polyethylene Glycol
Polyethylene glycol (PEG) is a hydrophilic polymer made from repeating units of

ethylene oxide and is shown in figure 2.3. The polymer is also named polyethylene oxide
(PEO) and polyoxyethylene (POE). PEG is commonly used to refer to polymers with
molecular weights below 20,000 Da while polymers with molecular weights greater than
20,000 Da are commonly referred to as PEO. POE is used to describe all weights of the
polymer.
O
OH

HO
z

Figure 2.3

Polyethylene Glycol (PEG)

The polymer behavior is based on temperature, solvent, molecular weight and the
concentration of the polymer. When the polymer is synthesized, it may have a
distribution of molecular weights. Separation techniques are used to sort the polymer
chains on a size basis. The polydispersity index (PDI) is a measure of how similar the
molecules are to one another in size and weight (equation 2.3). It can be calculated by
the ratio in the number average molar mass (equation 2.1) and the weight average molar
mass (equation 2.2).
= ( ΣniMi / ΣMi )

Equation 2.1

= ( ΣwiMi / Σwi )

Equation 2.2

PDI =

/

Equation 2.3

PEG has been used in a variety of drug delivery applications. Conjugation of PEG
to peptides and proteins is used modify their behavior in the body. Since PEG is highly
water soluble, it can be used to modify proteins and drugs that are not very soluble in
aqueous solutions [120]. PEG conjugation can be used to control the membrane
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permeability of small molecules used as chemotherapeutic agents [121]. It is also used to
modify protein and peptide circulation time while maintaining bioavailability and
slowing enzymatic degradation [122-125].
PEG can also be conjugated or adsorbed onto the surface of small particles or
vesicles. The addition of the polymer to the surface helps to slow the attachment of serum
proteins that tag the particles for removal [126]. This approach has been used in liposome
production to hide them from phagocytes, creating stealth liposomes [12, 15, 127-135].
Another benefit of PEG conjugation is steric stabilization of the particle by physically
separating the vesicle membranes from one another thereby preventing vesicle fusion
[136].
The conformation of the grafted PEG chains is dependent on the distance between
surface attachment points (D) and chain length of the polymer (R). There are three
primary conformations: pancake (D>>R), mushroom (D>R) and brush (D≤R) with
transition phases between them. For a PEG chain of 2000 Da (PEG 2000), the pancake
conformation is typical when the PEG surface concentrations are 1.3 mol%. Mushroom
conformation is found when PEG surface concentrations are at 4.5 mol%. At higher PEG
concentrations of 9 mol%, the polymer interaction forces the chains to extend into the
brush conformation [137]. In liposomes, it has been shown that PEG 2000 with a 5 mol%
surface concentration extends blood circulation times compared to liposomes without the
PEG chains. For the immuno-niosome vesicle design, a bifunctional PEG 2000 was used.
2.3.0

Molecule Synthesis
Vesicles used as drug carriers can be constructed, loaded and functionalized using

a variety of methods and chemistries. Drug-loaded niosomes that can be functionalized
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after construction by using a linker molecule activated by adjustment to an alkaline pH,
provide a functionalization method that is simple and nondestructive to the encapsulated
therapeutic agent. The surfactant is modified to form a functionalized surfactant molecule
that can be used to create the niosome vesicles.
Table 2.0

Immuno-niosome Materials

Material description

Catalog number

Manufacturer

Tween 61

P-3065

Sigma-Aldrich

Span 60

85546

Fluka

Omega-Hydroxyl alpha-

HO-PEG2000-NH2

JenKem Technology Co.,

amino PEG, MW 2000 Da

Ltd.

Cholesterol

362794-5G

Sigma-Aldrich

N,N-diisopropylethylamine,

387649-100ML

Sigma-Aldrich

Chloroform

AC61028-1000

Acros Organics

Dicetyl phosphate

101546

MP Biomedicals, LLC

Cyanuric chloride

C95501

Sigma-Aldrich

redistilled

2.3.1

Functionalized Non-Ionic Surfactant
Polyoxyethylene sorbitan monostearate (Tween 61) is a non-ionic surfactant with

a fatty acid hydrophobic tail structure composed primarily of stearic acid and a
hydrophilic head group with three short polyoxyethylene chains. The linker molecule
cyanuric chloride (CC), is covalently attached to the surfactant through nucleophilic
substitution to the hydroxyl group on the terminal end of one of the polyoxyethylene
chains. Tween 61, dissolved in dry chloroform and CC in a 0.8 molar ratio of [CC:Tween
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61] in the presence of a 3 fold molar ratio of N,N-diisopropylethylamine (DIPEA) are
mixed together. To form the functionalized surfactant Tween-CC, the mixture is placed in
a 50 ml round bottom flask attached to a sealed rotary evaporator under a nitrogen
atmosphere for 36 hours. Next, an intermediate molecule is created by covalently binding
the amine group on the bi-functional PEG molecule to the previously functionalized
Tween-CC surfactant in a 0.9 molar ratio [PEG:Tween-CC] in the presence of 2 fold
molar ratio of DIPEA. To functionalize this intermediate molecule, CC is covalently
bound to the terminal hydroxyl group on the PEG chain in a 0.8 molar ratio [CC:TweenCC-PEG] in the presence of 2 fold molar DIPEA for 36 hours to form Tween-CC-PEGCC. The reaction steps are shown in figure 2.4.
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Figure 2.4

PEGylated Surfactant Synthesis
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2.3.2

Functionalized Cholesterol
In addition to the functionalized PEGylated molecule described in section 2.3.1, a

second functionalized molecule was synthesized to provide options for targeted drug
delivery. Cholesterol is a fat soluble molecule that can be incorporated in vesicles and
micelles made from non-ionic surfactants. Using functionalized micelles, lipophilic and
hydrophobic agents that would normally destabilize a bilayer membrane can be delivered
to a specific target. The cyanuric chloride (CC) functionalized cholesterol provides a site
for antibody conjugation that is in close proximity to the vesicle surface, thereby
enhancing the fusibility of the vesicle with the endothelial cell outer membrane. This
occurs when the vesicle is less than 2nm from the cell surface and provides an additional
delivery strategy. The synthesis was carried out as previously described. The cholesterol
dissolved in dry chloroform was reacted for 36 hours with CC in a 1:0.9 molar ratio in the
presence of DIPEA under a nitrogen atmosphere. The CC replaces the hydroxyl head
group on the cholesterol molecule forming the molecule cholesterol-CC as shown in
figure 2.5.
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Figure 2.5
2.4.0

Functionalized Cholesterol Synthesis

Vesicle Synthesis
Vesicle formation is a multi-step process driven by the reduction of the

amphiphile surfactant molecule energy state that forms ordered, non-covalent structures
as described in section 2.1.0. Membrane formation is a process that requires a
temperature-dependent phase change and mechanical shear forces. The materials used are
a combination of surfactant, functionalized surfactant, cholesterol and an electrostatic
agent. The ratios of materials are derived from previous studies where a 1:1:0.01 molar
ratio of cholesterol, surfactant and an electrostatic agent respectively, provide a stable
membrane structure. Here, dicetyl phosphate (DCP) is used as the electrostatic agent
since it provides a slight negative charge which helps the formed vesicles repel one
another in solution.
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2.4.1

Thin Film Formation and Hydration
The first step in vesicle formation is the production of lamella that are formed

from the materials in round bottom glass flasks on a rotary evaporator. Functionalized
and non-functionalized non-ionic surfactants, cholesterol and dicetyl phosphate are
dissolved in chloroform. The mixture is reduced under a nitrogen atmosphere at low
pressures. When the solution is reduced to a thin film, the pressure is reduced to 50 bar
for 2 hours and then purged with nitrogen under atmospheric pressure at 4 L/min to
remove trace chloroform from the film.
To form vesicles, the thin films are hydrated using an aqueous solution containing
a hydrophilic drug or dye. The aqueous solution is placed in a round bottom flask on a
sealed rotary evaporator that has been purged with nitrogen. The temperature is raised
above the gel crystalline phase using a hot water bath and a shear force is applied by
rotation of the flask on a rotary evaporator to separate the lamella into sheets to form a
combination of multilayer and bilayer vesicles in solution.
2.4.2

Vesicle Extrusion
To control the vesicle size distribution, a barrel extruder (LIPEX™, Northern

Lipids Inc.) and polycarbonate membranes are used. The membranes are commercially
available with uniform pore sizes ranging from 1um down to 50 nm, allowing control of
the desired extruded vesicle size. The extruder is surrounded by a water jacket in order to
maintain the extrusion temperature above the gel crystalline phase. The raw solution of
multilayer vesicles (MLVs) and bi-layer vesicles (BLVs) is loaded into the extruder and
pushed across the polycarbonate membranes using high pressure nitrogen gas. Multiple
passes are performed to create uniform vesicle dispersions in the bulk solution.
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2.4.3

Size Exclusion Chromatography Introduction
Size exclusion chromatography (SEC) is a method used to separate molecules

from a solution based on their size. Other types of SEC include: gel filtration
chromatography (GFC)-aqueous system and gel permeation chromatography (GPC) –
non-aqueous system, used for polymer separation. Both types of SEC use a nonadsorptive stationary phase to eliminate any reactive process of the sample with the
stationary phase. The separation process is driven by two primary phenomena, diffusion
and exclusion. This is accomplished by placing the sample in a column with a porous
packing material stationary media. The material allows small molecules to diffuse within
the stationary packing material while the larger molecules are excluded by size, and flow
freely around the packing material. This difference in traveling time or retention time
allows for sample separation as shown in figure 2.6.
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Sephadex
Dye
Niosomes

FLOW

Diffusion

Exclusion

Figure 2.6
2.4.3.1

Size Exclusion Chromatography

SEC Volumetric Theory
The separation process is based on the variation in hydrodynamic sizes of the

sample molecules to be processed and their interaction with the packing material. The
porosity of the packing material and the packing geometry create the volumetric
parameters that are used to describe how the sample elutes from the column.
-

Equation 2.4

This volumetric distribution is described by equation 2.4, where Kav is the average
volumetric distribution coefficient, Ve is the elution volume, Vt is the total volume, or
the sum of the outer (Vo) and the inner volume (Vi) of the packing material, sephadex. Vi
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is the inner volume of the packing material and is equal to Vt-Vo. Ve-Vo is the retention
volume and if the packing material particles do not retain the solute (sample), then the
value of Kav=0. A graphical depiction is shown in figure 2.7.

Figure 2.7
2.4.3.2

Size Exclusion Chromatography Elution Profile

SEC Methods
In fluorescent dye loaded niosome production, the formed vesicles must be

separated from the free (unencapsulated) dye. The bulk sample containing dye-loaded
niosomes and free dye is injected in a column that is packed with small porous spheres
made from cross-linked dextran (Sephadex). To prevent the vesicles from collapsing or
swelling, the aqueous solvent phase used is phosphate buffered saline solution with the
same osmotic strength as the dye solvent. An Akta Prime (GE Healthcare)
chromatography system equipped with a pH probe, conductivity probe, pressure sensor,
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mercury lamp and UV filter set is used for the separation. The column is a 70 cm model
XK 16 and is used for separating large bulk samples up to 2 ml, however we have found
that sample sizes of 500 ul avoid fouling in the entrance, causing back mixing of the
sample. Figure 2.8 is the elution profile of a 2 ml sample where the peak spread from
where the sample clogged the packing material as it entered the column.

Figure 2.8

Elution Profile from 2 ml Sample Size

Figure 2.9 is the elution profile from a 500 ul sample that was injected into the column.
The narrow peak shows that the sample was able to pass through the entrance without
fouling the packing material to the point that causes back mixing of the sample.
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Figure 2.9
2.4.4

Elution Profile from 500 ul Sample Size

Antibody Conjugation
Immuno-niosomes are created when antibodies are conjugated to the exterior

surface of the niosomes. This procedure is conducted at room temperature (25°C) on an
orbital shaker table for 16 hours. First, the conjugation is initiated by adjusting the pH of
the niosome solution to 8.8 as described by Bendas and Hood [16, 17]. At pH 8.8, the
chloride groups on the cyanuric chloride molecule are activated and thus a covalent bond
is formed via nucleophilic substitution with one of the disulfide groups on the Fc region
of the IgG as shown in figure 2.10.
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Figure 2.10

Antibody Conjugation

After antibody conjugation, the solution is loaded in a disposable PD-10
chromatography column packed with sephadex G-25. The immuno-niosome fraction is
eluted with one column volume of 0.01M phosphate buffered saline. The pH of the
sample is verified and adjusted if necessary. The excess unconjugated antibodies can be
recovered by subsequent column elution.
2.5.0

Vesicle Metrology
To determine vesicle size stability and dispersion properties, a variety of methods

were used to gather data on the niosomes after synthesis. The methods include
chromatography, microscopy, flow cytometry and dynamic light scattering techniques.
2.5.1

Thin Layer Chromatography Introduction
Thin layer chromatography (TLC) provides an economical method of sample

analysis without the need for expensive equipment and materials typically used in high
performance liquid chromatography (HPLC). Although HPLC is more sensitive and can
detect trace concentrations it is recommended as a follow-up procedure to TLC. TLC is
also recommended for development and optimization of the solvent system used for the
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separation. The flat plates allow for visual inspection of the separation. Samples that have
components that interfere with the separation or are at concentrations below the limit of
detection will need to be preprocessed by separation or concentration respectively prior to
using TLC. Separation can be completed using a simple solvent partitioning procedure
(Folch method, [138]), ion exchange columns [139] or solid phase extraction columns
[140].
The TLC separation process is based on a mobile phase composed of a
combination of solvents that carry the sample up the plate by convective forces and a
stationary phase acting as the adsorbent and attracting the sample to the matrix by
hydrogen bonds and dipole interactions. The solvent system contains polar and nonpolar
solvents creating an organic/inorganic partition on the plate. The sample is separated into
its components as the mobile phase moves up the plate.
2.5.1.1

Thin Layer Chromatography Methods
Table 2.1

TLC Materials

Item

Description

Manufacturer

TLC Plates

20 x 20, Silica Gel 60Å , 250um

Whatman®

Fluorescent Indicator.

Catalog No: 4861-820

TLC Tank

Glass 25 cm x 25 cm Tank

Fisher

Micro-Pipettes

1 Lambda (1 ul)

Drummond # 1-000-0010

Micro-Pipettes

5 Lambda (5 ul)

Drummond # 1-000-0050

Atorvastatin

Atorvastatin Calcium

Pfizer

Chloroform

Solvent

Fisher
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Table 2.1 (Continued)
Item

Description

Manufacturer

Diethyl Ether

Solvent

Fisher

Hexane

Solvent

Fisher

Acetic Acid

Solvent

Fisher

Methanol

Solvent

Fisher

UV Lamp

254nm Ultraviolet hand held lamp

Cole Parmer

Camera

35mm SLR digital , EOS 20D

Cannon

For the TLC separation, 20x20 cm glass plates coated with a thin layer of silica
(stationary phase) impregnated with a fluorescent indicator were used. When the TLC
plate is exposed to ultraviolet light, the separated components block the fluorescent signal
as indicated by a dark spot on the plate. If the component of interest does not fluoresce or
absorb, a stain can be applied to the plate which will react with or stain the separated
component so it can be imaged.
Atorvastatin calcium was encapsulated in a previously designed immunoniosome. TLC analysis was used to determine the actual concentration of atorvastatin
calcium within the immuno-niosomes. Some of the samples were processed prior to TLC
separation to concentrate and separate components. Standards were applied directly to the
plate using disposable glass capillary tubes (microcap). Two solvent systems were
chosen. The first separation was completed in chloroform (a proton donor), methanol
(polar) and 4% acetic acid in a [45:55:4] volumetric ratio. The second development was
completed using hexane (as the diluent), diethyl ether (proton acceptor), and acetic acid
in a [80:20:1.5] volumetric ratio. The methanol and chloroform form a partition on the
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plate based on their polarity. The hexane and ether are used to separate lipids and
cholesterol. The acetic acid is used as a solvent modifier to reduce tailing of the sample
during separation when lipids are present.
2.5.1.2

Thin Layer Chromatography Results
The plates are analyzed using an open software routine in MATlab, that

determines the spot density from an image (shown in Figure 2.11) taken with a 35mm
SLR digital camera [141]. The plate is illuminated by a mounted 254nm lamp. The focal
distance of the camera, position of the lamp and position of the sample spot are held
constant.

Figure 2.11

TLC Image Analysis

The calibration curve in Figure 2.12 was generated using known concentrations of pure
atorvastatin dissolved in methanol. The standards were directly spotted onto the TLC
plate and then developed. The linearity of the standards (R2 =0.9898) shows the sample
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follows the Beer-Lambert law [142]. Standards and unknowns are included on each TLC
plate to allow for comparison between plates. To determine the actual encapsulation of
atorvastatin used to treat apolipoprotein E knockout mice, immuno-niosome samples
were dehydrated on a vacuum concentrator and reconstituted using methanol. The
atorvastatin dissolves freely in methanol while cholesterol and Span 60 (niosome
components) do not. Samples were rehydrated in 1/10th the volume of the original sample
in order to concentrate the drug. Additionally, standards were separated on the same plate
to provide a concentration reference. It was determined that the concentration of
atorvastatin encapsulated in the immuno-niosomes was 1.68E-05 mg/ml, well below the
expected concentration of 0.15 mg/ml.

Atorvastatin Standards
Optical Density

25

y = 1E+09x + 12.63
R² = 0.9898

20
15

AV Standards

10

Linear (AV Standards)

5
0
1E-10 2.1E-09 4.1E-09 6.1E-09 8.1E-09
Moles of atorvastatin

Figure 2.12
2.5.2

Atorvastatin Standards

Fluorescent Microscopy
Fluorescent microscopy is used to confirm specific binding of the immuno-

niosomes to cell surface receptors. The antibody conjugation to the immuno-niosomes is
also imaged using this technique. Materials may exhibit fluorescent behavior when they
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have been excited by a beam of light. Fluorescence was first described by Stokes when he
noticed that some minerals emitted visible light when an invisible source light was used
to illuminate them [143]. This process can be described in three steps using a simple
Jablonski diagram (Figure 2.13).

Figure 2.13

Jablonski Diagram

First, the energy state of the molecule is increased by the absorption of light from a
source. The second step is the release of a photon from the molecule after it has been
excited by an external source. The third step is the energy level drop to the normal state
after the release of a photon. This energy difference between the two states is called the
“Stokes shift” and was described by Alexander Jablonski in 1935 [144]. Fluorescence
microscopy takes advantage of the ability to separate a specific spectrum of light that is
emitted from a molecule by using optical filters. To confirm antibody conjugation to the
functionalized surfactant, large vesicles (>1um) were produced with 5% functionalized
PEG2000 to create the PEGylated immuno-niosomes. Immuno-niosomes conjugated with
fluorescein isothiocyanate (FITC) labled antibodies are shown by the arrow in figure 2.14
(400X magnification).
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100um

Figure 2.14

PEGylated FITC Conjugated Immuno-niosomes

Another type of functionalized molecule was synthesized to provide alternative
conjugation strategies that are described in section 5.3.0. This was accomplished using
cholesterol and functionalizing the molecule with the cyanuric chloride linker chemistry.
Confirmation of the functionalized cholesterol was accomplished by imaging large
vesicles (>1um) that were conjugated with fluorescently tagged antibodies. Figure 2.15 is
a black and white image taken of the fluorescent tagged immuno niosomes made with
10% functionalized cholesterol (200x magnification, bright spots indicate fluorescent
tagged immuno-niosomes).

Figure 2.15

FITC Conjugated Immuno-niosomes Using Functionalized Cholesterol
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2.5.3

Flow Cytometry
Flow cytometry is a technique used to examine cells and microscopic particles in

suspension. For the experiments shown below, an LSR II flow cytometer (Becton
Dickinson) was used. Cells or particles are either tagged with a fluorescent labeled
antibody or a fluorescent dye can be encapsulated in the particles. The particles are
suspended and move in a flowing stream through a laser path. Median fluorescent
intensity and forward and side scatter from the dye and particle is detected using a
photomultiplier tube. Forward scatter data is used to indicate cell volume and side scatter
data is used to examine the complexity of internal structures of the cell or particle. Flow
cytometry is commonly used to count fluorescently labeled cells in a mixed population.
In this study it was used to confirm antibody conjugation and provide a map of the
population distribution of the vesicles, to confirm data collected using dynamic light
scattering instrumentation. Immuno-niosome samples were conjugated with Fluorescein
isothiocyanate (FITC) labeled goat anti rat IgG antibodies. Figures 2.16 and 2.17 and
tables 2.2 and 2.3 show forward and side scatter data along with median fluorescence
intensity for the two populations from a sample of 5% PEGylated immuno-niosomes that
were hydrated with phosphate buffered saline and conjugated with FITC labeled IgG.
Figure 2.18 is dynamic light scattering data for the same sample illustrating the two
different size vesicle populations. Previously the immuno-niosomes size was controlled
using extrusion techniques and size exclusion chromatography. By combining these size
and purification techniques 99.7% of the population was the same size.
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Figure 2.16

Figure 2.17

5% PEG Sample Forward Scatter Distribution

5% PEG Sample Particle Size Distribution
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P1

Figure 2.18

5% PEG Sample Dynamic Light Scattering Data

Table 2.2

Table 2.3

P2

5% PEG Sample Event Population

5% PEG Sample Median Distribution

Fluorescent dye loaded niosomes were prepared using 10% functionalized
cholesterol. To maintain large vesicle sizes, the niosomes were not extruded. However
they were vortexed to create large vesicles and then separated from the free dye using
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size exclusion chromatography. The different sized fractions were mixed together.
Forward scatter data illustrating the three different population sizes is shown in figure
2.19 and table 2.4. The three different population sizes are also shown using dynamic
light scattering as shown in figure 2.20.
Table 2.4

Figure 2.19

10% Functionalized Cholesterol Median Population

10% Functionalized Cholesterol Forward Scatter Distribution
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P2
P1

Figure 2.20
2.5.4

P3

10% Functionalized Cholesterol Sample Dynamic Light Scattering Data

Transmission Electron Microscopy
Transmission electron microscopy (TEM) is used to provide sample images with

high resolution and magnification that cannot be achieved with light microcopy. This is
accomplished in a device that shoots a focused beam of electrons through the sample.
The signal can be detected using an electronic camera or the resulting beam can be
viewed on a phosphorus screen. A beam of high energy electrons emanate from an
electron gun that is passed through a very thin section of material to produce images. The
electron beam must be under vacuum to prevent unwanted molecular interactions.
Table 2.5

Transmission Electron Microscopy Materials

Item

Description

Manufacture

2% glutaraldehyde

Fixative made from 50%

Fisher

stock
2% Osmium Tetroxide

Fixative and contrast stain
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EMS

Table 2.5 (continued)
2% Uranyl Acetate

Stain

EMS

Acetone

Solvent

Fisher

Ethanol

Anhydrous agent

Fisher

Propylene Oxide

Solvent

EMS

Embed 812

Resin

EMS

Araldite 502

Resin

EMS

Dodecenyl Succinic

Anhydride

EMS

Accelerator

EMS

Lead Nitrate

Stain

EMS

Sodium Citrate

Stain

EMS

1N Sodium Hydroxide

Reagent

Fisher

20nm Gold Particles

Electron dense marker

EMS

5nm Iron Oxide particle

Magnetic particle

Oceannanotech

Copper Grids

Sample holder TEM

EMS

Formvar Coated Grids

Sample holder TEM

EMS

Anhydride
2,4,6-tridimethylamino
methyl phenol (DMP-30)

A transmission electron micrograph of the solution containing 5% PEGylated
surfactants hydrated with 0.01M phosphate buffered saline is shown in figure 2.21 The
solution was stained with uranyl acetate, placed on a formvar coated carbon grid and
imaged. The arrows indicate multi-layer membranes from the vesicles in the bulk
solution.
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Figure 2.21

TEM of Bulk Solution

A transmission electron micrograph of niosomes prepared with 5% PEGylated
surfactant and hydrated with 0.01M phosphate buffered saline is shown in figure 2. The
vesicles were treated with osmium tetroxide to stabilize the vesicle membrane through
chemical fixation. The vesicle suspension was placed on a formvar coated carbon grid,
dried and imaged.
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Figure 2.22

TEM of Extruded 5% PEGylated Niosomes

A transmission electron micrograph of 5% PEGylated surfactant niosomes containing
5nm paramagnetic FeO particles in 0.01M phosphate buffered saline is shown in figure
2.23. The vesicle suspension was placed on a formvar coated carbon grid, dried and
imaged.

Figure 2.23

TEM of 5% PEGylated FeO-Loaded Niosomes
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2.5.5

Dynamic Light Scattering
Dynamic light scattering (DLS) is also known as photon correlation spectroscopy

(PCS) or quasi-elastic light scattering (QLS). DLS uses the physics of small particle
behavior to correlate data from light scattered by the particles in solution [145, 146]. The
sample is placed into a cuvette and a monochromatic light source such as a laser is passed
through the sample (figure 2.24). The scattered light that has collided with the particles in
the sample is collected and the data is analyzed.

Figure 2.24

Dynamic Light Scattering

The theory of dynamic light scattering is based on Brownian motion caused by
thermal energy causing random motion of a particle in solution. For spherical particles
the relationship of the radius and the diffusion coefficient (equation 2.5) is given by the
Stokes Einstein equation [147], where the diffusion coefficient (D) is equal to the
mobility of the particle (μp) multiplied by Boltzmann’s (kB) constant and the absolute
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temperature (T). The mobility (equation 2.6) of a particle is the ratio of the particle’s
terminal drift velocity (Vp) to an applied force (F). The Boltzmann’s constant (equation
2.7) relates the energy of the microscopic particle to the energy level of the macroscopic
surroundings. It is the gas constant (R) divided by Avogadro’s number (NA). Applying
Stokes law for frictional force (Fd) (equation 2.8), the drag coefficient γ is formed
(equation 2.9) with R being the particle radius and μ being the viscosity of the fluid.
Using Stokes law, the Einstein equation becomes a relationship of the apparent diffusion
coefficient and the radius of the particle (equation 2.10) that can be rearranged to yield
the apparent radius of a particle when the diffusion coefficient is known (equation 2.11)
[148].
D = μpkBT

Equation 2.5

μp= Vp / F

Equation 2.6

kB= R / NA = 1.38E-23 [JK-1]

Equation 2.7

Fd = 6πRVμ

Equation 2.8

γ = 6πRμ

Equation 2.9

D = (kB T) / (6π R μ) [m2s-1]

Equation 2.10

RApp = (kB T) / (6π μ DApp)

Equation 2.11

In dynamic light scattering data analysis, the light scattered from the sample is
used to determine the time it takes for the particle to move from its original starting
position. The correlation function is used to relate the change in time and the difference
of the current position of the particle compared to its original position. At low
concentrations, the correlation function can relate the size of the particle to the
temperature and the viscosity of the fluid. A graph of the correlation function for a
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niosome sample is shown in figure 2.25. On the left side near time =0, the correlation of
the position of the particle to its original position is equal to one, meaning the starting
position of the particle is directly related to its current position. As time increases, this
relationship is eventually lost and there is no correlation of the current position of the
particle to where it originated. The rate of decay is used to calculate the radius of the
particles.

Figure 2.25

Niosome Sample Correlation Data

Niosomes containing Span 60 and 10% Tween or Span 60 and 5% PEG, were
placed in sealed cuvettes and measured every 7 days over a 90 day period. Care was
taken not to disturb the samples during the time course and particle sedimentation was
noted in the non-PEGylated niosome samples. The results from these data suggest the
PEG had a positive effect in maintaining vesicle suspension and size dispersion, shown in
figure 2.26
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5% PEG
10% Tween

Figure 2.26

Data from Stability Comparison Study on Day90
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3.

Evaluation of Receptor-Conjugated Vesicles
Binding studies were conducted to investigate immuno-niosome interactions with

endothelial cells. Several methods were used to gather data to ensure the results were not
biased by the detection technique. Most of the techniques were based on an encapsulated
fluorescent dye to detect the cell bound immuno-niosomes. Gold particles were
encapsulated for transmission electron microscopy experiments.
3.1.0

Cell Culture
Primary bovine aortic endothelial cells (BAEC) and endothelial basal media

(EBM-2) were purchased from Lonza. The cells were plated at an average density of
6.7x105 cells/cm2 and grown in T-25 culture flasks (Costar) using EBM-2 supplemented
with 10% heat inactivated calf serum and 100 units/ml penicillin and 100 ug/ml
streptomycin in a humidified 5% CO2/95% air incubator at 37°C. When the cells reached
85% confluency, aliquots were frozen back in a 50:50 (V:V) mixture of supplemented
EBM-2 and DMSO supplemented cryopreservative (Profreeze, Cambrex Bio Science).
Endothelial cells used in binding experiments were allowed to proliferate in tissue
culture flasks to a cell viability of 98% prior to high density plating and were used from
passage 2 to passage 5. The cells were rinsed three times with 0.01M phosphate buffered
saline solution (PBS) and then were detached from the flask bottom using 4%
trypsin/EDTA in 0.01M PBS for 2 minutes. The cells were collected and resuspended in
serum-supplemented EBM-2 to neutralize the trypsin. The suspension was centrifuged at
900 Gs to form a cell pellet. The cell pellet was resuspended in fresh supplemented EBM73

2 and plated onto growing surfaces of choice, i.e. flasks, glass slides, glass cover slips or
96 and 24 multi-well plates. The glass slides and cover slips were cleaned with 100%
ethanol (ETOH) and dried prior to steam sterilization. For some experiments, the glass
surfaces were treated with sterile 1M NaOH for 30 minutes and rinsed with 0.1M PBS
three times to improve cell adhesion.
3.2.0

Fixed Cell Binding
Fixed endothelial cells under static conditions were used to determine the binding

efficiency of the PEGylated immuno-niosomes (INs) to endothelial cells. For receptor
specific binding, the cells were treated with the cytokine, tumor necrosis factor alpha
(TNF-α), to invoke an inflammatory response in the endothelial cells for expression of
the targeted cell surface receptors. This was accomplished by treating the cells with 20
ng/ml TNF-α in supplemented EBM-2 for 24 hours before the experiment. After
incubation with TNF- α, the cells were chemically fixed to preserve the receptors to
prevent internalization or turnover of the expressed receptors over long time courses. The
cells were fixed with a solution made from 2% glutaraldehyde in 0.01M PBS to maintain
the osmotic balance in the sample. The fixation causes cross linking between protein
molecules. Glutaraldehyde was used for the fixation because it is a larger molecule than
formaldehyde and is able to bridge greater distances. For some experiments the
commercial preservative Histochoice was used since it has less auto-fluorescence signal
than glutaraldehyde. After fixation, the cells were rinsed three times with 0.01M PBS.
Some PBS was left on the cells after the last rinse to maintain sample moisture. It was
removed just prior to immuno-niosome sample application.
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The niosome concentration is indicated by the total surfactant content of the
sample. Black plastic 96 well culture plates with clear bottoms were used for the
experiments using fluorescent dye to reduce signal cross talk between wells. BAEC were
plated and grown as previously described in section 3.1.0. The cells were treated with
TNF-α for 24 hours, fixed and the treated with a 2% solution of normal goat serum in
0.01M PBS to block nonspecific binding. The cells were then incubated with fluoresceinloaded immuno-niosomes that were conjugated with CD44, clone KM201. The
PEGylated immuno-niosomes were compared to the previous immuno-niosome design to
determine the effect of the PEG tether used for antibody conjugation. The endothelial
cells were incubated for 5, 10, 15, 30, 60 and 120 minutes with 1.5, 3, and 6 mM of 10%
Tween immuno-niosomes or 5% PEGylated immuno-niosomes at 37°C. Following
incubation, each cell well was rinsed three times with 0.01M PBS to remove unbound
immuno-niosomes. The plate was imaged on a Typhoon 9410 flat bed fluorescent
scanner (GE Healthcare) using the 488nm laser to excite the fluorescent dye. Data was
collected at 528nm with a setting of 600volts on the photomultiplier tube, a pixel size of
100 microns and a focal plane of 3mm to account for the distance from the bottom of the
plate to the imaging surface. The cell density was determined by treating the cells with a
solution of 20ng/ml propidium iodide and using excitation/emission of 535/620nm on the
Typhoon. The raw data was analyzed with Quantity One software. For each well, the
fluorescent volume was calculated by taking 5 mm regions of interest at 5 different
locations. The error bars in figures 3.0 and 3.1, indicate the standard deviation for the
measurement. The results from the vesicle comparison study showed an increase in the
binding performance of the 5% PEGylated INs over the previous 10% Tween IN design.
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This was most evident with the higher vesicle concentration and longer incubation times.
The results of the vesicle comparison study are shown in figures 3.0 and 3.1, and the data
is summarized (percent difference in binding) in table 3.0.

10% Tween Static Binding Results
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Figure 3.0

Fixed Cell Binding: 10% Tween Fluorescein-loaded IN (CD44, KM201)

5% PEG Static Binding Results
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Figure 3.1

Fixed Cell Binding: 5% PEG Fluorescein-loaded IN (CD44, KM201)
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Table 3.0

3.3.0

Static Binding Results

Time

6mM %

3mM %

1.5mM %

[minutes]

Diff.

Diff.

Diff.

5

1.21

0.84

2.12

10

1.16

1.82

1.73

15

3.11

0.44

4.63

30

1.93

2.10

6.37

60

10.76

8.03

7.96

120

17.00

9.25

12.82

Live Cell Binding
We sought to determine how the immuno-niosomes interacted with live cells and

to confirm BAEC uptake of the immuno-niosomes using CD44 as the target receptor. A
study comparing the CD44 receptor to other receptors was conducted using
carboxyrhodamine 110 fluorescent dye loaded immuno-niosomes conjugated with CD44,
ICAM-1 or VCAM-1 antibodies. Confocal microscopy was used to confirm uptake using
the CD44 receptor and to examine binding patterns between ICAM-1 and CD44 INs
binding to the BAEC.
3.3.1

Multiwell Plate Experiments
Two different experiments were conducted using live cells grown in multiwell

plates to provide IN and active cell surface receptor binding data. For both experiments
the cells were grown and plated as previously described in section 3.1.0. In the first
experiment, cells were plated in black plastic 96 well tissue culture plates with clear
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bottoms and grown until they were 85% confluent. This experiment was designed to
determine if antibodies that target different receptors have similar nonspecific binding
properties. To determine nonspecific binding, the cells were not treated with cytokines
prior to incubation with the immuno-niosomes. The immuno-niosomes were conjugated
with ICAM-1, VCAM-1 or the CD44 antibody. A control vesicle was not conjugated
with antibodies. A 3mM immuno-niosome solution in Dulbecco’s Modified Eagle
Medium (DMEM) was used for the experiment. Cells were incubated with immunoniosomes or control vesicles for 0.5, 1.0, 2.0 and 4.0 hours in a humidified 5% CO2/95%
air incubator at 37°C.
Each cell well was rinsed three times with 0.01M phosphate buffered saline (PBS)
to remove unbound vesicles. The plate was imaged on a Typhoon 9410 flat bed
fluorescent scanner (GE Healthcare) using the 488nm laser to excite the fluorescent dye.
Data was collected at 528nm with a setting of 600volts on the photomultiplier tube, a
pixel size of 100 microns and a focal plane of 3mm. The cell density was determined by
treating the cells with a solution of 20ng/ml propidium iodide and imaging using an
excitation/emission of 535/620nm on the Typhoon. The results of the experiment indicate
that the nonspecific binding is antigen independent as shown in figure 3.2
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Nonspecific Binding Results
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Figure 3.2

Nonspecific Binding Results

The second experiment was designed to compare the binding performance of the
different receptor-targeted immuno-niosomes to live cells. The cells were plated in black
plastic 24 well tissue culture plates with clear bottoms and grown until they were 85%
confluent. Control cells were not treated while the other cells were treated with 20ng/ml
TNF-α for 24 hours. Then all the cells were treated with a 2% solution of normal goat
serum in 0.01M PBS to reduce nonspecific binding prior to incubation with the immunoniosomes. The immuno-niosomes were conjugated with ICAM-1, VCAM-1 or the CD44
antibody. A control vesicle was not conjugated with antibodies. A 1.5mM immunoniosome solution in DMEM was used in the experiment. Cells and antibody conjugated
immuno-niosomes or control vesicles were incubated for 1, 2 and 4 hours in a humidified
5% CO2/95% air incubator at 37°C. Each cell well was rinsed three times with 0.01M
phosphate buffered saline (PBS) to remove unbound vesicles. The plate was imaged on a
Typhoon 9410 flat bed fluorescent scanner (GE Healthcare) using the 488nm laser to
excite the fluorescent dye. Data was collected as previously described. The cell density
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was determined by treating the cells with a solution of 20ng/ml propidium iodide and
imaging using an excitation/emission of 535/620nm on the Typhoon. The results of the
experiment indicate that by four hours post-immuno-niosome binding, the three antigens
have similar binding to the endothelial cells as shown in figure 3.3.
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Figure 3.3
3.3.2

Live Binding Performances

Confocal Laser Scanning Microscopy
Confocal microscopy was used to determine binding characteristics of the

immuno-niosomes (INs) to activated bovine aortic endothelial cells (BAECs). Confocal
microscopy uses multiple focal planes, called the z-stack to reconstruct images. Each
plane is scanned with a focused beam of laser light. This is accomplished one line at a
time over the surface from one end of the image to the other. The software that
reconstructs the images uses a setting called maximum projection. This setting uses the
maximum average intensity from each plane to reconstruct the compiled image. This
method is an improvement over standard fluorescent microscopy since data from the outof-focus plane is not used, providing better image contrast and resolution.
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Two types of experiments were conducted using confocal microscopy. The cells
were grown as previously described in section 3.1.0 and plated in 8 well glass tissue
culture chamber slides (Lab Tek II, Fisher Scientific). In the first experiment, the cells
were activated using an injury model. The injury was created by scratching the cells in
each well in an “x” pattern with a 200ul pipet tip, 24 hours prior to incubation with the
INs. The INs were loaded with 1mM carboxyrhodamine 110 dye since it is more photo
stable than fluorescein-based dyes. The INs were conjugated with either ICAM-1 or
CD44 antibodies and incubated with the injured cells for one hour. The cells were rinsed
three times with 0.01M phosphate buffered saline (PBS) solution before fixation with
Histochoice fixative to preserve the cells and bound vesicles. The slides were coverslipped with a number 1.5 glass cover and mounting media containing 4',6-diamidino-2phenylindole (DAPI) stain to identify the cell nucleus. DAPI is a stain that when bound to
double stranded DNA fluoresces approximately 20 times greater than DAPI alone. An
image of the cells and ICAM-1 INs from the injury model is shown in figure 3.4, with
arrows pointing at the injury border. The fluorescent intensity of across the injury (ROI
1) is shown in figure 3.5.
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Figure3.4

Figure 3.5

One Hour Scratch Injury ICAM (200X Magnification)

Graph of Fluorescent Intensity from Region of Interest 1

The injury model was used to compare the binding of ICAM-1 and CD44 antibodies
against the receptors expressed by the injured endothelial cells. Figure 3.6 is an image of
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how the regions of interest were located; the results are shown in table 3.1 (fluorescence
± standard deviation).

Figure 3.6

Injury Model Region of Interest (200X Magnification)
Table 3.1

Injury Binding Results

Pixel Density

CD44

ICAM-1

Injured ROI

1052828(+/-993.21)

383184(+/- 325.96)

Non Injured ROI

633041(+/-543.01)

179019(+/- 168.65)

Difference

419787

204165

Uptake of the antibody conjugated immuno-niosomes into the activated
endothelial cells was confirmed in the second set of experiments using confocal
microscopy techniques. The INs were loaded with 1mM Carboxyrhodamine 110
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fluorescent dye, extruded across 200nm polycarbonate membranes and purified using
size exclusion chromatography. The dye loaded niosomes had an average size of 168nm
based on dynamic light scattering data. The INs were conjugated with CD44, ICAM-1 or
VCAM-1 antibodies. The cells were grown as previously described in section 3.1.0 and
plated in 8 well glass tissue culture chamber slides and grown until they were 85%
confluent. The cells were treated with 20 ng/ml TNF-α for 24 hours before being treated
with a 2% solution of normal goat serum in 0.01M PBS for one hour to reduce
nonspecific binding prior to incubation with the immuno-niosomes. The cells were
incubated with a 3mM solution of immuno-niosomes in Dulbecco’s modified eagle
medium (DMEM) for 1, 2, 3 and 4 hours. The cells were rinsed three times with 0.01M
PBS before fixation with Histochoice fixative to preserve the cells and bound vesicles. A
5 ug/ml solution of wheat germ agglutinin conjugated to Alexa Fluor 633 (WGA Alexa
Fluor 633, Invitrogen) in 0.01M PBS was used to stain the cell membrane. The slides
were cover-slipped with a number 1.5 glass cover-slip and mounting media containing
4',6-diamidino-2-phenylindole (DAPI) nucleic acid stain to identify the cell nucleus. In
figures 3.7 through 3.13, the carboxyrhodamine 110 fluorescent dye is shown in green.
Figures tagged with an (A) indicate TNF-α activated endothelial cells and figures tagged
with a (B) indicate control endothelial cells that were not treated with TNF-α.
Internalized dye within the cell is indicated by the arrow in figure 3.7(A). Endothelial
cells with no injury or TNF-α treatment served as the control as shown in figure 3.7(B).
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A

Figure 3.7

B

(A) 4 Hour PEGylated CD44 Immuno-niosomes, (B) Control, 4 Hour
PEGylated CD44 Immuno-niosomes, (630X Magnification)
B

A

Figure 3.8

(A) 3 Hour PEGylated CD44 Immuno-niosomes, (B) Control, 3 Hour
PEGylated CD44 Immuno-niosomes, (630X Magnification)
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B

A

Figure 3.9

(A) 2 Hour PEGylated CD44 Immuno-niosomes, (B) Control, 2 Hour
PEGylated CD44 Immuno-niosomes, (630X Magnification)
A

Figure 3.10

B

(A) 1 Hour PEGylated CD44 Immuno-niosomes, (B) Control, 1 Hour
PEGylated CD44 Immuno-niosomes, (630X Magnification)

Figures 3.8 (A and B) shows endothelial cells that were incubated for 3 hours
with PEGylated CD44 conjugated immuno-niosomes. The arrows point at immunoniosomes that have formed clusters on lipid rafts on the cellular membrane as they are
being internalized. Figures 3.9 (A and B) show endothelial cells that were incubated for 2
hours with PEGylated CD44 conjugated immuno-niosomes. The clusters of immunoniosomes have formed, but they are not as distinct as the clusters in the 3 and 4 hour
incubations. This suggests that the endocytotic pathway involves lipid rafts and clustering
of cell surface receptors. Figures 3.10 (A and B) show endothelial cells that were
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incubated for 1 hour with PEGylated CD44 conjugated immuno-niosomes. The immunoniosomes are bound to the cell surface but have not formed clusters as seen with longer
incubation times. Internalization is confirmed by the Z-stack images shown in figure 3.11
(A-D) showing the internalized dye in the 1-4 hour treated samples (A) from figures 3.73.10.

Figure 3.11

(A-D) Z-stack of the 1-4 Hour PEGylated CD44 Immuno-niosomes,
(630X Magnification)
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To compare immuno-niosome binding to endothelial cells using a different
antigen. PEGylated niosomes were conjugated with VCAM-1. Endothelial cells
incubated for four hours with PEGylated VCAM-1 conjugated immuno-niosomes are
shown in figures 3.12 (A and B). The arrows point at immuno-niosomes that have formed
clusters on lipid rafts on the cell membrane, similar to PEGylated immuno-niosomes that
were conjugated with CD44.

A

Figure 3.12

B

(A) 4 Hour PEGylated VCAM-1 Immuno-niosomes, (B) Control, 4 Hour
PEGylated VCAM-1 Immuno-niosomes, (630X Magnification)

Confocal microscopy was also used to image immuno-niosomes made from
functionalized cholesterol. The steroid was functionalized with cyanuric chloride as
previously described in section 2.3.2 and immuno-niosomes were made with 10%
functionalized cholesterol loaded with 1mM carboxyrhodamine 110 and conjugated with
ICAM-1 antibodies. The cells were grown and plated in 8 well glass tissue culture
chamber slides. They were treated with 20 ng/ml TNF-α followed by 2% goat serum
prior to incubation with immuno-niosomes as previously described. Figure 3.13 (A) and
(B) are images of endothelial cells incubated for 4 hours with immuno-niosomes made
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with 10% functionalized cholesterol. The vesicles appear to have formed dense clusters
on the endothelial cell surface.

A

Figure 3.13

B

(A) 4 Hour ICAM Cholesterol Immuno-niosomes, (B) Control, 4 Hour
ICAM Cholesterol Immuno-niosomes (630X Magnification)

3.3.3

Transmission Electron Microscopy
Transmission electron microscopy (TEM) was used to image immuno-niosomes

loaded with albumin coated 20nm gold nanoparticles. Gold is an electron dense material
that provides a strong signal when viewed with TEM. The immuno-niosomes were
conjugated with antibodies that target the CD44 cell surface receptor. Endothelial cells
were grown in T-25 culture flasks as previously described in section 3.1.0. The cells were
treated with 20 ng/ml TNF-α in supplemented EBM-2 for 24 hours. The cells were fixed
with 2% glutaraldehyde in 0.01M phosphate buffered saline (PBS) for 15 minutes. The
cells were washed three times with 0.01M PBS to remove excess glutaraldehyde. The
cells were treated with 2% osmium tetroxide (OsO4, a heavy metal compound that is used
as a fixative and a stain) for 30 minutes and rinsed with deionized water three times to
remove excess osmium and salts. The cells were removed from the flasks using a cell
scraper and were recovered by centrifugation at 900g to form a cell pellet. Since epoxide
89

resins are not miscible with water, the samples must be dehydrated. To protect the cells
during this process, the dehydration is done slowly and great care is taken to ensure the
samples do not dry completely between steps by ensuring the sample is always covered in
solution. Samples are dehydrated for 2 minutes each step in 20% (v/v), 30%, 50%, 70%,
90% ethanol at 4°C followed by 100% ethanol at room temperature and 100% ethanol at
4°C. Prepared resin (Appendix A, note 1) is diluted with solvent in a 1:1 (v/v) ratio. The
cell pellets are immersed in this solution for one hour and agitated to ensure adequate
infiltration of the cells. The cells are spun at 900g for 5 minutes to form a pellet and the
excess resin is removed and replaced with pure resin at room temperature for one hour.
This step is repeated one additional time. To embed the samples, the cell pellets are then
placed in labeled casting trays with pure resin and heated to 60°C for 24-48 hours to
polymerize the resin.
Thick sections of the embedded cells are cut and stained with semeithin stain and
viewed using light microscopy to inspect the samples. Then thin sections, 50-70um, are
cut from the embedded samples and floated on prepared mesh grids (Appendix A, note 2)
and placed sample side up for drying in petri dishes lined with filter paper. Uranyl acetate
(UA) staining of the thin sections is performed by prepping a disposable 4-well petri dish
with a section of dental wax and adding a drop of prepared UA stain (Appendix A, note
3) corresponding to each grid to be stained. Grids with samples are placed sample side
down on the UA stain for 10 minutes. The samples are washed with deionized water in a
series of three beakers. The grids are agitated by moving the sample vertically in each
beaker. The washed grids are placed on the filter paper and dried before lead staining.
Lead staining is performed on dry grids as follows. The petri dish is prepared as
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previously described. Sodium hydroxide (NaOH) pellets (to remove CO2) are placed in
the chamber with the dental wax. Prepared lead citrate stain is added (Appendix A, note
4). The grids are floated sample side down on the drops of lead stain for 1-3 minutes. The
grids are washed as before in a series of three beakers filled with deionized water and
allowed to dry sample side up on filter paper. A transmission electron micrograph taken
at 30kv of gold loaded, internalized PEGylated CD44 conjugated immuno-niosome is
shown in figure 3.14. The arrow points to gold particles that have been internalized inside
the endothelial cell. The arrow in figure 3.15 points to a gold loaded PEGylated CD44
conjugated immuno-niosome bound to the cell membrane. Because gold is not
metabolized, sections of tissue samples from the liver and spleen (from in vivo
experiments) would provide information on how the immuno-niosomes interact with the
organs.

Figure 3.14

Gold Loaded, Internalized Immuno-niosomes
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Figure 3.15
3.4.0

Gold Loaded Immuno-niosome Bound to Cell Membrane

pH Sensitive Dye Study
When the endothelial cell internalizes the targeted delivery vesicle by the process

of endocytosis, the process can be tracked by using a fluorescent agent that shifts
spectrum with changing pH conditions. A family of pH sensitive dyes,
seminaphthorhodafluor-carboxylic acid (SNARF), can be used to track such
environmental pH changes. [149-156, 157 ]. It was hypothesized that encapsulation of the
pH sensitive dye could be used to track the different steps associated with vesicle
internalization [158-161]. It is well understood that cellular internalization pathways
utilize vacuoles that employ a pH change. This intracellular change creates a condition
that causes conformational changes in proteins, thus enabling the sorting and recycling of
cellular receptors to the cell surface. Endocytosis is a multistep process that can involve
multiple transport vacuoles such as early endosomes, late endosomes and lysosomes
[162]. This process can be monitored by using an indicator to determine the time course
of the pH shift in the micro environment. Carboxy SNARF-4 was selected for the study
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based on reports of SNARF-1 interacting with the liposome membrane [163]. Samples of
SNARF-4 dye were placed in a steady state spectrofluorometer (ISS PC1) to gather
spectral data from the dye at different pH values. The stock solution of dye was diluted to
a 1μM concentration in 0.01M phosphate buffered saline solution and the pH was
adjusted using 1N hydrochloric acid. The samples were excited at 488nm and the spectra
of the 1μM SNARF-4 dye, with a pH ranging from 5.45 to 7.2 were recorded as shown in
figure 3.16.
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Figure 3.16

Fluorescence Spectra of 1 μM SNARF-4 in PBS, pH 5.45 to 7.2

There was a strong pH dependent shift in the SNARF-4 dye spectra. It shifted
from 650 nm at a pH of 7.2 to 580 nm at pH 5.4. This data suggested the dye could
indicate the intracellular pH changes in the different cellular compartments. Therefore 1
μM SNARF-4 dye was encapsulated in niosomes made from Span 60, cholesterol and
dicetyl phosphate. The samples were then placed into the spectrofluorometer and the
spectra at various emission wavelengths were recorded. When the SNARF-4 loaded
niosomes at a pH of 7.2 were excited at 488nm, the spectrum showed a peak at 520 nm
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(figure 3.16). This result was unexpected, therefore the experiment was repeated using
new samples of niosomes loaded with SNARF-4 dye. The results of the two experiments
confirmed the spectra of the SNARF-4 loaded niosomes had a peak at 520 nm when
excited at 488 nm at a pH of 7.2, as shown in figure 3.17.
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Spectrum of SNARF-4 Loaded Span 60 Niosomes at pH 7.2

The spectra of the individual components of the niosomes were recorded to determine the
source of the 520 nm emission peak. Cholesterol was found to fluoresce with a strong
signal when placed in 0.01M phosphate buffered saline solution, the same concentration
was to make niosomes at a pH of 7.2 (figure 3.18). The ring structure of cholesterol
shown in figure 2.2 is thought to be the source of the signal.
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Figure 3.18
3.5.0

Spectrum of Cholesterol

Vesicle Binding in Flow
In preparation for in vivo studies, the confirmation of the ability of PEGylated

CD44 conjugated immuno-niosomes to bind to endothelial cells in flow was confirmed
using a parallel plate flow chamber (CytoDyne, La Jolla, CA.). The chamber was
attached to a syringe pump as shown in figure 3.19.

Glass slide

Waste

Syringe pump

Flow cell
Figure 3.19

Flow Cell

Endothelial cells were cultured as previously described in section 3.1.0. Cells were plated
at a density of 2x103 total cells on 75 mm x 38 mm glass slides that were steam sterilized
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and treated with 1M sodium hydroxide. The cells were grown to 80% confluency before
treatment with 20 ng/ml TNF-α for 24 hours. The cells were fixed with a solution made
from 2% glutaraldehyde in 0.01M phosphate buffered saline (PBS) and rinsed to remove
excess glutaraldehyde. A 60 ml syringe was loaded with 0.01M PBS and the system was
primed with 10 ml PBS to remove any air. The slide was placed on the flooded chamber
then vacuum was applied to hold the slide in place. Before starting the pump, a 2ml bolus
injection of a 3mM solution of PEGylated CD44 conjugated immuno-niosomes loaded
with 5mM 5(6)carboxyfluorescein was injected upstream of the chamber. Then the pump
was started and 50 ml of PBS was eluted at a flow rate (Q) of 14 ml/min through the
chamber. Using equation 3.0, the calculated endothelial cell shear stress (τ) was 10.4
dynes/cm2, using a viscosity (μ) of 9x10-3dyn/s*cm2, channel height (h) of 2.2x10-2 cm
and a channel width (b) of 2.5 cm[164].
τ = (6Qμ) / (bh2)

Equation 3.0

Fluorescence microscopy was used to verify immuno-niosome binding in flow to
endothelial cells placed in the parallel plate flow chamber. The samples were post stained
with 4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI) to determine the location of
the cell nucleus. The arrows in figure 3.20 point at bound vesicles on the endothelial
cells.

Figure 3.20

PEGylated CD44 Conjugated Immuno-niosomes Bound to Endothelial
Cells Under Flow Conditions (400x Magnification)
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4.

Enhancement of the Modified Vesicle Designs for Targeted Delivery in Vivo
To determine the bio-distribution of the immuno-niosomes in vivo it is necessary

to use a fluorescent dye where there is minimal imaging interference from living tissues,
e.g. hemoglobin, collagen, cholesterol and water. A near infrared dye with a maximum
emission spectrum of 800 nm was used (IRDye 800CW carboxylate, LiCor Biosciences).
4.1.0

Multi Well Plate Imaging
Free and encapsulated IRDye 800CW was imaged using an in vivo imaging

system (Xenogen IVIS Spectrum, Caliper Life Sciences). Both epi and trans-illumination
methods were used to measure fluorescence intensity at excitation/emission 745/800 nm.
Figure 4.0 shows a 96 well plate with two concentrations of IRDye 800CW (A1-3)
1nmol, (B1-3) 4 nmol and (C1-3) 0.01M phosphate buffered saline solution (PBS). The
minimum IRDye 800CW concentration detectable using epi-illumination with a 5 second
exposure time was 1 nmol.

Figure 4.0

IRDye 800CW Bulk Solutions

In the next experiment, 0.01M PBS was encapsulated in 5% PEG and 10% Tween
niosomes (figure 4.1 A1-3 and B1-3 respectively). IRDye 800CW was encapsulated in
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5% PEG niosomes in 1 nmol (Lane D1-3) and 4 nmol (Lane C1-3) concentrations. Three
different volumes of the samples, 100 ul (column 3), 200 ul (column 2) and 300 ul
(column 1) were imaged using epi-illumination (5 second exposure, F2 aperture, small
binning) and the image is shown in figure 4.2. It was determined that the PBS loaded
niosomes did not have a signal that would interfere with the dye, and that 4 nmol IRDye
800CW loaded niosomes were required for imaging at these settings.

Figure 4.1

IRDye 800CW Reference Samples

Based on these results, niosomes were loaded with 4 nmol IRDye 800CW, extruded
across 200 nm polycarbonate films and purified using size exclusion chromatography
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(SEC) as described in Section 2.4.3. Three volumes of 4 nmol IRDye 800CW loaded
niosomes, 300, 200, 100 ul (Row A, B, C respectively in Figure 4.2) were imaged to
confirm previous results The results shown in Figure 4.2 show that the method is
repeatable and that extruded, SEC purified niosomes loaded with 4 nmol IRDye800CW
can be imaged using epi-illumination on the Xenogen IVIS Spectrum.

Figure 4.2
4.2.0

4nmol IRDye 800CW Loaded 5% PEGylated Niosomes

Phantom Mouse Imaging
To determine preliminary concentrations of fluorescent dye and immuno-

niosomes for in vivo studies, a synthetic mouse called the phantom mouse was used to
image samples of niosomes loaded with the IRDye800CW fluorescent dye. IVIS
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Spectrum generated epi-illumination images of pipettes loaded with free and
encapsulated 4, 8, and 12 fmol IR800CW dye (1,2 and 3ul of 4 nM dye) as shown in
figure 4.3.

Figure 4.3

IRDye 800CW Pipette Standards for Phantom Mouse
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Figure 4.4

Minimum Detection Limits with Epi-illumination

To determine the limit of detection for the IRDye800CW loaded niosomes, the
phantom mouse was imaged in the ventral position with a 12 fmol IRDye 800CW loaded
niosome sample for 1 second with F1 aperture, high lamp, binning set at level 4 with epiillumination as shown in Figure 4.4. For comparison the phantom mouse was placed in
the dorsal position and the same sample was imaged using trans-illumination, shown in
figure 4.5. The sample emitted a signal of 2.6E9 photons/sec/cm2 when imaged for 5
seconds F2 aperture, high lamp, binning at level 4. Results indicate the niosome and dye
concentrations are adequate for pilot in vivo imaging studies.
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Figure 4.5

Phantom Mouse Imaged Under Trans-illumination
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5.

Discussion and Future Direction

5.1.0

Vesicle Design and Manufacturing
Many vesicle designs have been developed to transport therapeutic agents to

specific sites in the body. While no one design provides a solution for every application,
techniques using bilayer membranes to entrap therapeutic agents have proven successful.
Polymers provide vesicle stability, but the harsh conditions used for the polymerization
process can be detrimental to the agent being entrapped. Amphiphiles made from
peptides are easily metabolized in the body making them biocompatible. However,
because the molecules can be broken down so easily, the vesicle life span is low, and
spontaneous release of the entrapped drug can cause toxic dosage levels. In the niosome
production, the use of synthetic non-ionic surfactants provides an economical and
physiological advantage compared to traditional phospholipids used in liposome
production. Because phospholipids have the tendency to oxidize over time, great care
must be taken to ensure the product remains safe for use. Synthetic surfactants also have
an advantage because surfactants derived from natural sources require extra processing to
ensure there are no pathological contaminants.
The 200 nm size chosen for the niosome design provides an internal volume that
can contain a substantial dosage of the therapeutic agent, yet is small enough to evade
opsonization (coating of the vesicles by plasma proteins) and recognition by the
reticuloendothelial system. The 200 nm size is large enough to eliminate the non-specific
uptake of the vesicles through the process of cellular pinocytosis. The 200 nm size also
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allows the vesicle to remain in suspension for an extended period of time. The addition of
polyethylene glycol to the niosome (PEGylation) provides a mechanical boundary
between vesicles. This steric stabilization further enhances the stability of the niosome
suspension. The PEG chains also reduce the attachment of plasma proteins to the
niosome membrane surface. This is a very important feature that has been shown by other
groups to increase the circulation time of the vesicle in vivo.
Targeting specific endothelial cell surface receptors allows for intravenous
delivery of the vesicles. This route delivers all of the vesicles to the blood where they will
encounter the endothelial cells lining the vessel walls. CD44, an inflammatory receptor
expressed by activated endothelial cells after cytokine exposure or physical injury, is the
targeted receptor. The CD44 receptor is also present on many cancer cells and provides a
method of delivering a therapeutic vesicle directly to the tumor. In addition to targeting
CD44, ICAM-1 and VCAM-1, other inflammatory receptors expressed by endothelial
cells were targeted, and binding of PEGylated immuno-niosomes (IN) with the three
different receptors types was compared. We investigated nonspecific binding and the
ability of the PEGylated immuno-niosomes to bind fixed and live endothelial cells. We
showed by confocal microscopy that PEGylated immuno-niosomes can be internalized by
the endothelial cell when they bind to the CD44 receptor (figure 3.11). This suggests that
the targeting scheme is capable of delivering therapeutics to specific cells.
Two methods were used to stimulate the upregulation of inflammatory cell
surface receptors. One method was the exposure of the cell to the pro-inflammatory
cytokine, tumor necrosis factor alpha (TNF-α). This is a well described process that has
been used in vitro to mimic the natural process of inflammation. An injury model was
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used to investigate the capacity of the PEGylated immuno-niosomes to target cells that
have experienced physical trauma.
The concentration of atorvastatin encapsulated in immuno-niosomes was
determined using thin layer chromatography (TLC). It was found that two solvent
systems were required to separate all the immuno-niosome components from the
atoravastatin. The atorvastatin-loaded immuno-niosomes were pre-processed prior to
TLC separation to remove the surfactant and to concentrate the sample. Using known
atorvastatin concentrations, a standard curve was created. We determined that this TLC
separation method gave us the ability to accurately determine concentration as indicated
by the linear correlation coefficient (R2) of 0.9898 between the known and unknown
atorvastatin concentrations.
In the previous immuno-niosome design developed in our lab by Hood et al.,
cyanuric chloride was used to link the Tween 61 and CD44 antibody used to target the
niosome to the endothelial cells. In the work reported here, polyethylene glycol with
cyanuric chloride linking chemistry was added to this previous design, creating the
PEGylated immuno-niosome (figure 1.0). The linker chemistry was used to attach and
functionalize the PEG to the head group of the Tween 61 surfactant. The size and amount
of PEG used was based on previous liposome designs [12-15] and the results from the
fixed cell binding experiments (figures 3.0 and 3.1) which showed improved binding of
PEGylated CD44-IN as compared with CD44-IN to the activated endothelial cells. The
current PEGylated INs contain PEG surfactant on both the interior and exterior of the
vesicle. The immuno-niosome design can be further modified by incubating niosomes
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with PEGylated micelles to created PEGylated immuno-niosomes with the PEG only on
the immuno-niosome outer surface.
Therapeutic agent or dye entrapment occurs during the thin film hydration
process. This process time was extended from one to four hours, keeping other conditions
constant, to provide a bulk solution that was more homogenous than previously obtained.
Use of a more homogenous bulk solution lessened the previously seen fouling of the
polycarbonate membranes used for vesicle extrusion. With a bulk solution hydration time
of one hour, the membranes in the extruder needed to be replaced after four passes. When
the hydration time of the bulk solution was extended to two hours, eight-ten passes
through the extruder could be accomplished before the membranes fouled. When the
hydration time of the bulk solution was extended to four hours, the number of passes
before the membranes fouled approached 20. The high number of passes translates to
better size control of the vesicles and lower numbers of vesicles becoming entrapped in
the extruder membranes (less waste).
After bulk solution extrusion, the encapsulated and free therapeutic agent or dye
was separated using size exclusion chromatography. This type of separation results in
some sample loss and sample dilution. Under theoretical conditions, separation of
vesicles based on size is based on the assumption that there are no entrance or exit effects
from the column. However, empirically we showed that when the sample was loaded on
the column, the interaction of the bulk solution and the entrance region caused back
mixing (figure 2.8). The sample volume loaded on the column was reduced from 2 ml to
500 µl (figure 2.9). The reduction in sample volume loaded resulted in symmetric elution
profiles where the vesicle size correlated with the elution fraction. To determine PEG
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incorporation efficiency in the niosomes, the bulk solution was spiked with free PEG.
The spiked sample was loaded and eluted through the column. The resulting elution
profile showed an extra peak that was not present in samples that were not spiked with
free PEG. These results indicated that the PEG modified surfactant was incorporated in
the PEGylated niosome (results not shown).
A difference in PEGylated niosome versus niosome size distribution was
determined using dynamic light scattering. The addition of PEG to a vesicle can alter the
niosome solution viscosity and change its light absorbance properties which will affect
data collected using dynamic light scattering. To minimize the effects of the PEG on the
PEGylated niosome size distribution measurements, the samples were diluted with 0.01
M phosphate buffered saline, to maintain osmolarity and prevent PEGylated niosome
rupture. The large dilution of the PEGylated niosome sample caused the sample viscosity
to approach pure solvent (phosphate buffered saline). The size distribution changed by
only 4 nm, indicating that the PEG did not affect PEGylated niosome size distribution
and that the original measurements were valid. The PEGylated niosome size distribution
was also measured using transmission electron microscopy (figures 2.17 and 2.18) and
flow cytometry (figures 2.11 and 2.12, tables 2.0 and 2.1). The PEGylated niosome size
distribution supports the original measurements using dynamic light scattering (figure
2.13).
5.2.0

Experimental Conclusions
The binding efficiency of the PEGylated and non-PEGylated immuno-niosomes

to tumor necrosis factor alpha (TNF-α)-activated endothelial cells was compared. The
endothelial cells were plated in black/clear bottom multiwell culture plates. 5,6107

Carboxyfluorescein was encapsulated in the PEGylated CD44-IN and CD44-IN to
visualize binding to the endothelial cells. To prevent the endothelial cell surface receptors
from being internalized or recycled over the two hour experimental time course, the cells
were fixed prior to incubation with the PEGylated CD44-IN or CD44-IN. Binding of the
PEGylated CD44-IN to activated endothelial cells was increased 17% over binding of the
CD44-IN to activated endothelial cells (figures 3.0, 3.1, table 3.0). These data
demonstrate that PEGylation of the immuno-niosomes improves specific binding to
activated endothelial cells.
Next, experiments were conducted to determine the non-specific binding of the
PEGylated immuno-niosomes to live endothelial cells. Fluorescent dye was encapsulated
in the PEGylated CD44-IN, VCAM-1-IN and ICAM-1-IN to visualize binding. Nonspecific binding of the PEGylated CD44-IN, VCAM-1-IN and ICAM-1-IN to unactivated
endothelial cells was measured. It was determined that non-specific binding was linear
over the four hour time course (Figure 3.2). These data demonstrate that non-specific
binding of the PEGylated IN to the unactivated endothelial cells was not antibody
dependent.
Next, experiments were conducted to determine the interaction of the PEGylated
immuno-niosomes with live endothelial cells. Fluorescent dye was encapsulated in the
PEGylated CD44-IN, VCAM-1-IN and ICAM-1-IN to visualize binding. The endothelial
cells were activated with TNF-α for 24 hours prior to incubation with the PEGylated IN
to induce an inflammatory response. Specific binding of the PEGylated CD44-IN,
VCAM-1-IN and ICAM-1-IN to the activated endothelial cells was measured. It was
determined that all three PEGylated IN had similar binding to the activated endothelial
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cells over the four hour time course (Figure 3.3). These data suggest that the use of
antibodies on the PEGylated IN that target CD44 is as effective as those that target
VCAM-1 or ICAM-1.
Next, experiments were conducted to confirm uptake of the PEGylated immunoniosomes by activated endothelial cells. Fluorescent dye was encapsulated in the
PEGylated CD44-IN, VCAM-1-IN and ICAM-1-IN to visualize binding and uptake to
activated endothelial cells using a confocal microscopy. The images captured provided
confirmation that the immuno-niosome payload was internalized by the endothelial cells
(Figures 3.7-3.13). This was a major accomplishment that had not been seen before using
the vesicle design and antibody combination.
Next, experiments were conducted to determine the interaction of the PEGylated
immuno-niosomes with physically injured endothelial cells using confocal microscopy.
The cells were injured 24 hours prior to incubation with 5,6-carboxyrhodamine loaded
immuno-niosomes that were conjugated with CD44 or ICAM antibodies. The results
indicated the immuno-niosomes can target endothelial cells that have sustained trauma
from a physical injury (Figures 3.4, 3.5 and 3.6, Table 3.1). This is another important
finding and the results suggest that injuries sustained from battlefield wounds can be
targeted by therapeutic immuno-niosomes. This also means that the immuno-niosome
could deliver therapeutic agents to venous grafts after coronary surgery.
5.3.0

Future Directions
Experiments designed to determine the performance of the PEGylated immuno-

niosomes in vivo have been approved and funded through the Signature Interdisciplinary
Program In Cardiovascular Research (SIPCVR), a pilot grant program funded by USF
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Health. The proposed experiments will assist us in determining the bio-distribution of the
CD44, ICAM or VCAM conjugated immuno-niosomes in apolipoprotein E knockout
(apoE -/-) mice and wild type control mice (C57BL/6). The data will also give insight to
the pharmacokinetics (described in section 1.1.1) of the PEGylated immuno-niosomes invivo. The experimental design is to target sites of vascular inflammation caused by
atherosclerosis in the apo-E -/- mice. The mice will be injected with fluorescent dye
loaded immuno-niosomes, fluorescent dye loaded niosomes without antibodies or free
dye. Near infrared fluorescent dye, IRDye 800cw will be used so the animals can be
imaged live using the Xenogen IVIS Spectrum (described in section 4.2.0). The organs
will be imaged whole and then sectioned to give greater detail of the interactions and
binding of the immuno-niosomes with organs and cells.
The next experiments will be based on the information gained from, the pilot
study. To improve endothelial cell binding in large arteries, modification to the immunoniosome design will be made using the functionalized cholesterol (described in section
2.3.2) and a biotinylated PEG to conjugate both antibodies and selectins, respectively.
These modifications will provide a design that will allow the immuno-niosome to attach
with low affinity to the vessel wall via selectin binding and then roll to a site of
inflammation where the antibody can bind with high affinity, mimicking leukocyte
binding.
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Appendix A: Transmission Electron Microscopy Notes
note 1: Embedding resin is made by combining 13.75 grams of Embed 812, 8.5 grams
Araldite502 and stirring thoroughly without introducing bubbles. Then the resin
is activated by stirring in as before 27.5 grams of DDSA and 0.7-0.9 grams of
DMP-30.
note 2: The grids are prepared by sonicating them in technical grade acetone for one
minute followed by reagent grade acetone for one minute and finally in 95%
ethanol. Decant ethanol and invert petri dish over filer paper until grids fall from
the dish and have completely dried.
note 3: To make 50 ml of UA stain heat 50 ml DiH2O to 60 degrees Celsius. Under fume
hood add 0.5 grams of UA (CAUTION)to the heated DiH2O. Allow to cool and
do not agitate before use.
note 4: Simple lead citrate is prepared by adding 0.01-0.04 grams of lead citrate to 10ml
of freshly boiled and cooled H2O in a screw top vial. Then add 0.1ml of 10N
NaOH and shake until lead dissolves.
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